NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023 Article Swipe
Al B. Benson
,
Michael I. D’Angelica
,
Thomas A. Abrams
,
Daniel E. Abbott
,
Aijaz Ahmed
,
Daniel A. Anaya
,
Robert A. Anders
,
Chandrakanth Are
,
Melinda Bachini
,
David C. Binder
,
Mitesh J. Borad
,
Christopher L. Bowlus
,
Daniel B. Brown
,
Adam M. Burgoyne
,
Jason Castellanos
,
Prabhleen Chahal
,
Jordan M. Cloyd
,
Anne M. Covey
,
Evan S. Glazer
,
William G. Hawkins
,
Renuka Iyer
,
Rojymon Jacob
,
Lawrence J. Jennings
,
Robin Kate Kelley
,
Robin D. Kim
,
Matthew H. Levine
,
Manisha Palta
,
James O. Park
,
Steven S. Raman
,
Sanjay S. Reddy
,
Sean M. Ronnekleiv‐Kelly
,
Vaibhav Sahai
,
Gagandeep Singh
,
Stacey Stein
,
Anita Turk
,
Jean‐Nicolas Vauthey
,
Alan P. Venook
,
Adam C. Yopp
,
Nicole R. McMillian
,
Ryan Schonfeld
,
Cindy Hochstetler
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.6004/jnccn.2023.0035
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.6004/jnccn.2023.0035
In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.6004/jnccn.2023.0035
- https://jnccn.org/downloadpdf/journals/jnccn/21/7/article-p694.pdf
- OA Status
- bronze
- Cited By
- 164
- References
- 35
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4383896222
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4383896222Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.6004/jnccn.2023.0035Digital Object Identifier
- Title
-
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-07-01Full publication date if available
- Authors
-
Al B. Benson, Michael I. D’Angelica, Thomas A. Abrams, Daniel E. Abbott, Aijaz Ahmed, Daniel A. Anaya, Robert A. Anders, Chandrakanth Are, Melinda Bachini, David C. Binder, Mitesh J. Borad, Christopher L. Bowlus, Daniel B. Brown, Adam M. Burgoyne, Jason Castellanos, Prabhleen Chahal, Jordan M. Cloyd, Anne M. Covey, Evan S. Glazer, William G. Hawkins, Renuka Iyer, Rojymon Jacob, Lawrence J. Jennings, Robin Kate Kelley, Robin D. Kim, Matthew H. Levine, Manisha Palta, James O. Park, Steven S. Raman, Sanjay S. Reddy, Sean M. Ronnekleiv‐Kelly, Vaibhav Sahai, Gagandeep Singh, Stacey Stein, Anita Turk, Jean‐Nicolas Vauthey, Alan P. Venook, Adam C. Yopp, Nicole R. McMillian, Ryan Schonfeld, Cindy HochstetlerList of authors in order
- Landing page
-
https://doi.org/10.6004/jnccn.2023.0035Publisher landing page
- PDF URL
-
https://jnccn.org/downloadpdf/journals/jnccn/21/7/article-p694.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://jnccn.org/downloadpdf/journals/jnccn/21/7/article-p694.pdfDirect OA link when available
- Concepts
-
Medicine, Biliary tract cancer, Biliary tract, Intrahepatic Cholangiocarcinoma, Gallbladder cancer, Gallbladder, Internal medicine, Cancer, Multidisciplinary approach, Gastroenterology, General surgery, Intensive care medicine, Oncology, Gemcitabine, Social science, SociologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
164Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 80, 2024: 77, 2023: 7Per-year citation counts (last 5 years)
- References (count)
-
35Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4383896222 |
|---|---|
| doi | https://doi.org/10.6004/jnccn.2023.0035 |
| ids.doi | https://doi.org/10.6004/jnccn.2023.0035 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/37433432 |
| ids.openalex | https://openalex.org/W4383896222 |
| fwci | 82.61263881 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000175 |
| mesh[1].descriptor_ui | D001661 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | diagnosis |
| mesh[1].descriptor_name | Biliary Tract Neoplasms |
| mesh[2].qualifier_ui | Q000628 |
| mesh[2].descriptor_ui | D001661 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | therapy |
| mesh[2].descriptor_name | Biliary Tract Neoplasms |
| mesh[3].qualifier_ui | Q000175 |
| mesh[3].descriptor_ui | D005706 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | diagnosis |
| mesh[3].descriptor_name | Gallbladder Neoplasms |
| mesh[4].qualifier_ui | Q000628 |
| mesh[4].descriptor_ui | D005706 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | therapy |
| mesh[4].descriptor_name | Gallbladder Neoplasms |
| mesh[5].qualifier_ui | Q000175 |
| mesh[5].descriptor_ui | D018281 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | diagnosis |
| mesh[5].descriptor_name | Cholangiocarcinoma |
| mesh[6].qualifier_ui | Q000628 |
| mesh[6].descriptor_ui | D018281 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | therapy |
| mesh[6].descriptor_name | Cholangiocarcinoma |
| mesh[7].qualifier_ui | Q000175 |
| mesh[7].descriptor_ui | D008113 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | diagnosis |
| mesh[7].descriptor_name | Liver Neoplasms |
| mesh[8].qualifier_ui | Q000628 |
| mesh[8].descriptor_ui | D008113 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | therapy |
| mesh[8].descriptor_name | Liver Neoplasms |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D001650 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Bile Duct Neoplasms |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D001653 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Bile Ducts, Intrahepatic |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D006801 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Humans |
| mesh[12].qualifier_ui | Q000175 |
| mesh[12].descriptor_ui | D001661 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | diagnosis |
| mesh[12].descriptor_name | Biliary Tract Neoplasms |
| mesh[13].qualifier_ui | Q000628 |
| mesh[13].descriptor_ui | D001661 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | therapy |
| mesh[13].descriptor_name | Biliary Tract Neoplasms |
| mesh[14].qualifier_ui | Q000175 |
| mesh[14].descriptor_ui | D005706 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | diagnosis |
| mesh[14].descriptor_name | Gallbladder Neoplasms |
| mesh[15].qualifier_ui | Q000628 |
| mesh[15].descriptor_ui | D005706 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | therapy |
| mesh[15].descriptor_name | Gallbladder Neoplasms |
| mesh[16].qualifier_ui | Q000175 |
| mesh[16].descriptor_ui | D018281 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | diagnosis |
| mesh[16].descriptor_name | Cholangiocarcinoma |
| mesh[17].qualifier_ui | Q000628 |
| mesh[17].descriptor_ui | D018281 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | therapy |
| mesh[17].descriptor_name | Cholangiocarcinoma |
| mesh[18].qualifier_ui | Q000175 |
| mesh[18].descriptor_ui | D008113 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | diagnosis |
| mesh[18].descriptor_name | Liver Neoplasms |
| mesh[19].qualifier_ui | Q000628 |
| mesh[19].descriptor_ui | D008113 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | therapy |
| mesh[19].descriptor_name | Liver Neoplasms |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D001650 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Bile Duct Neoplasms |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D001653 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Bile Ducts, Intrahepatic |
| type | article |
| title | NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023 |
| biblio.issue | 7 |
| biblio.volume | 21 |
| biblio.last_page | 704 |
| biblio.first_page | 694 |
| topics[0].id | https://openalex.org/T11364 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Cholangiocarcinoma and Gallbladder Cancer Studies |
| topics[1].id | https://openalex.org/T11369 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9890999794006348 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Genetic factors in colorectal cancer |
| topics[2].id | https://openalex.org/T11067 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9876999855041504 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Colorectal Cancer Treatments and Studies |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.91634202003479 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C3017919176 |
| concepts[1].level | 4 |
| concepts[1].score | 0.6851217746734619 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q124292 |
| concepts[1].display_name | Biliary tract cancer |
| concepts[2].id | https://openalex.org/C2775982439 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6561616063117981 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3562150 |
| concepts[2].display_name | Biliary tract |
| concepts[3].id | https://openalex.org/C2909135397 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6418227553367615 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q124292 |
| concepts[3].display_name | Intrahepatic Cholangiocarcinoma |
| concepts[4].id | https://openalex.org/C2776534502 |
| concepts[4].level | 3 |
| concepts[4].score | 0.624519407749176 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q977787 |
| concepts[4].display_name | Gallbladder cancer |
| concepts[5].id | https://openalex.org/C2777148285 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5427278876304626 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q64386 |
| concepts[5].display_name | Gallbladder |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.49148476123809814 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C121608353 |
| concepts[7].level | 2 |
| concepts[7].score | 0.44554415345191956 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[7].display_name | Cancer |
| concepts[8].id | https://openalex.org/C22467394 |
| concepts[8].level | 2 |
| concepts[8].score | 0.41548678278923035 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q849359 |
| concepts[8].display_name | Multidisciplinary approach |
| concepts[9].id | https://openalex.org/C90924648 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3927786946296692 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[9].display_name | Gastroenterology |
| concepts[10].id | https://openalex.org/C61434518 |
| concepts[10].level | 1 |
| concepts[10].score | 0.36608922481536865 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q932510 |
| concepts[10].display_name | General surgery |
| concepts[11].id | https://openalex.org/C177713679 |
| concepts[11].level | 1 |
| concepts[11].score | 0.33542272448539734 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[11].display_name | Intensive care medicine |
| concepts[12].id | https://openalex.org/C143998085 |
| concepts[12].level | 1 |
| concepts[12].score | 0.333046555519104 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[12].display_name | Oncology |
| concepts[13].id | https://openalex.org/C2780258809 |
| concepts[13].level | 3 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q414143 |
| concepts[13].display_name | Gemcitabine |
| concepts[14].id | https://openalex.org/C36289849 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q34749 |
| concepts[14].display_name | Social science |
| concepts[15].id | https://openalex.org/C144024400 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q21201 |
| concepts[15].display_name | Sociology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.91634202003479 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/biliary-tract-cancer |
| keywords[1].score | 0.6851217746734619 |
| keywords[1].display_name | Biliary tract cancer |
| keywords[2].id | https://openalex.org/keywords/biliary-tract |
| keywords[2].score | 0.6561616063117981 |
| keywords[2].display_name | Biliary tract |
| keywords[3].id | https://openalex.org/keywords/intrahepatic-cholangiocarcinoma |
| keywords[3].score | 0.6418227553367615 |
| keywords[3].display_name | Intrahepatic Cholangiocarcinoma |
| keywords[4].id | https://openalex.org/keywords/gallbladder-cancer |
| keywords[4].score | 0.624519407749176 |
| keywords[4].display_name | Gallbladder cancer |
| keywords[5].id | https://openalex.org/keywords/gallbladder |
| keywords[5].score | 0.5427278876304626 |
| keywords[5].display_name | Gallbladder |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.49148476123809814 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/cancer |
| keywords[7].score | 0.44554415345191956 |
| keywords[7].display_name | Cancer |
| keywords[8].id | https://openalex.org/keywords/multidisciplinary-approach |
| keywords[8].score | 0.41548678278923035 |
| keywords[8].display_name | Multidisciplinary approach |
| keywords[9].id | https://openalex.org/keywords/gastroenterology |
| keywords[9].score | 0.3927786946296692 |
| keywords[9].display_name | Gastroenterology |
| keywords[10].id | https://openalex.org/keywords/general-surgery |
| keywords[10].score | 0.36608922481536865 |
| keywords[10].display_name | General surgery |
| keywords[11].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[11].score | 0.33542272448539734 |
| keywords[11].display_name | Intensive care medicine |
| keywords[12].id | https://openalex.org/keywords/oncology |
| keywords[12].score | 0.333046555519104 |
| keywords[12].display_name | Oncology |
| language | en |
| locations[0].id | doi:10.6004/jnccn.2023.0035 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S935620192 |
| locations[0].source.issn | 1540-1405, 1540-1413 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1540-1405 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of the National Comprehensive Cancer Network |
| locations[0].source.host_organization | https://openalex.org/P4324004213 |
| locations[0].source.host_organization_name | National Comprehensive Cancer |
| locations[0].source.host_organization_lineage | https://openalex.org/P4324004213 |
| locations[0].source.host_organization_lineage_names | National Comprehensive Cancer |
| locations[0].license | |
| locations[0].pdf_url | https://jnccn.org/downloadpdf/journals/jnccn/21/7/article-p694.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of the National Comprehensive Cancer Network |
| locations[0].landing_page_url | https://doi.org/10.6004/jnccn.2023.0035 |
| locations[1].id | pmid:37433432 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of the National Comprehensive Cancer Network : JNCCN |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/37433432 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5029706633 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5485-7227 |
| authorships[0].author.display_name | Al B. Benson |
| authorships[0].countries | BE, CH, CN, DE, GB, IN, JP, US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1320553840, https://openalex.org/I2948539688, https://openalex.org/I4210119928 |
| authorships[0].affiliations[0].raw_affiliation_string | research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I137982388, https://openalex.org/I4210099842, https://openalex.org/I4210103611 |
| authorships[0].affiliations[1].raw_affiliation_string | GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc., |
| authorships[0].affiliations[2].raw_affiliation_string | TheraBionic. |
| authorships[0].affiliations[3].institution_ids | https://openalex.org/I137982388, https://openalex.org/I189718659, https://openalex.org/I4210108457 |
| authorships[0].affiliations[3].raw_affiliation_string | Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals, |
| authorships[0].affiliations[4].institution_ids | https://openalex.org/I4210101899 |
| authorships[0].affiliations[4].raw_affiliation_string | Array BioPharma Inc., |
| authorships[0].affiliations[5].institution_ids | https://openalex.org/I189718659, https://openalex.org/I4210117523, https://openalex.org/I4210120269, https://openalex.org/I4210124059 |
| authorships[0].affiliations[5].raw_affiliation_string | Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd., |
| authorships[0].affiliations[6].institution_ids | https://openalex.org/I157075465 |
| authorships[0].affiliations[6].raw_affiliation_string | ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company, |
| authorships[0].affiliations[7].institution_ids | https://openalex.org/I4390039227 |
| authorships[0].affiliations[7].raw_affiliation_string | Robert H. Lurie Comprehensive Cancer Center of Northwestern University |
| authorships[0].affiliations[8].institution_ids | https://openalex.org/I1283582996, https://openalex.org/I2948663404, https://openalex.org/I4210088994, https://openalex.org/I4210103611 |
| authorships[0].affiliations[8].raw_affiliation_string | Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and |
| authorships[0].institutions[0].id | https://openalex.org/I4390039227 |
| authorships[0].institutions[0].ror | https://ror.org/02p4far57 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210147348, https://openalex.org/I4390039227 |
| authorships[0].institutions[0].country_code | |
| authorships[0].institutions[0].display_name | Robert H. Lurie Comprehensive Cancer Center of Northwestern University |
| authorships[0].institutions[1].id | https://openalex.org/I137982388 |
| authorships[0].institutions[1].ror | https://ror.org/04yzcpd71 |
| authorships[0].institutions[1].type | company |
| authorships[0].institutions[1].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[0].institutions[1].country_code | BE |
| authorships[0].institutions[1].display_name | Janssen (Belgium) |
| authorships[0].institutions[2].id | https://openalex.org/I1283582996 |
| authorships[0].institutions[2].ror | https://ror.org/02f9zrr09 |
| authorships[0].institutions[2].type | company |
| authorships[0].institutions[2].lineage | https://openalex.org/I1283582996 |
| authorships[0].institutions[2].country_code | CH |
| authorships[0].institutions[2].display_name | Novartis (Switzerland) |
| authorships[0].institutions[3].id | https://openalex.org/I4210088994 |
| authorships[0].institutions[3].ror | https://ror.org/008h8bh21 |
| authorships[0].institutions[3].type | company |
| authorships[0].institutions[3].lineage | https://openalex.org/I142395110, https://openalex.org/I4210088994 |
| authorships[0].institutions[3].country_code | CN |
| authorships[0].institutions[3].display_name | Astellas Pharma (China) |
| authorships[0].institutions[4].id | https://openalex.org/I157075465 |
| authorships[0].institutions[4].ror | https://ror.org/032hfv632 |
| authorships[0].institutions[4].type | company |
| authorships[0].institutions[4].lineage | https://openalex.org/I157075465, https://openalex.org/I4210091812 |
| authorships[0].institutions[4].country_code | DE |
| authorships[0].institutions[4].display_name | Bristol-Myers Squibb (Germany) |
| authorships[0].institutions[5].id | https://openalex.org/I189718659 |
| authorships[0].institutions[5].ror | https://ror.org/04x4v8p40 |
| authorships[0].institutions[5].type | company |
| authorships[0].institutions[5].lineage | https://openalex.org/I180857899, https://openalex.org/I189718659 |
| authorships[0].institutions[5].country_code | GB |
| authorships[0].institutions[5].display_name | Pfizer (United Kingdom) |
| authorships[0].institutions[6].id | https://openalex.org/I4210117523 |
| authorships[0].institutions[6].ror | https://ror.org/01w6gjq94 |
| authorships[0].institutions[6].type | company |
| authorships[0].institutions[6].lineage | https://openalex.org/I2250650973, https://openalex.org/I4210117523 |
| authorships[0].institutions[6].country_code | GB |
| authorships[0].institutions[6].display_name | Samsung (United Kingdom) |
| authorships[0].institutions[7].id | https://openalex.org/I4210099842 |
| authorships[0].institutions[7].ror | https://ror.org/01tvt4d48 |
| authorships[0].institutions[7].type | company |
| authorships[0].institutions[7].lineage | https://openalex.org/I188950975, https://openalex.org/I4210099842 |
| authorships[0].institutions[7].country_code | IN |
| authorships[0].institutions[7].display_name | GlaxoSmithKline (India) |
| authorships[0].institutions[8].id | https://openalex.org/I4210120269 |
| authorships[0].institutions[8].ror | https://ror.org/02v50dx14 |
| authorships[0].institutions[8].type | company |
| authorships[0].institutions[8].lineage | https://openalex.org/I4210120269 |
| authorships[0].institutions[8].country_code | JP |
| authorships[0].institutions[8].display_name | Taiho Pharmaceutical (Japan) |
| authorships[0].institutions[9].id | https://openalex.org/I2948539688 |
| authorships[0].institutions[9].ror | https://ror.org/02g5p4n58 |
| authorships[0].institutions[9].type | company |
| authorships[0].institutions[9].lineage | https://openalex.org/I2948539688 |
| authorships[0].institutions[9].country_code | US |
| authorships[0].institutions[9].display_name | AbbVie (United States) |
| authorships[0].institutions[10].id | https://openalex.org/I1320553840 |
| authorships[0].institutions[10].ror | https://ror.org/03g03ge92 |
| authorships[0].institutions[10].type | company |
| authorships[0].institutions[10].lineage | https://openalex.org/I1320553840 |
| authorships[0].institutions[10].country_code | US |
| authorships[0].institutions[10].display_name | Amgen (United States) |
| authorships[0].institutions[11].id | https://openalex.org/I4210119928 |
| authorships[0].institutions[11].ror | https://ror.org/02c7apg81 |
| authorships[0].institutions[11].type | company |
| authorships[0].institutions[11].lineage | https://openalex.org/I4210119928 |
| authorships[0].institutions[11].country_code | US |
| authorships[0].institutions[11].display_name | Apexigen (United States) |
| authorships[0].institutions[12].id | https://openalex.org/I4210101899 |
| authorships[0].institutions[12].ror | https://ror.org/018axtd57 |
| authorships[0].institutions[12].type | company |
| authorships[0].institutions[12].lineage | https://openalex.org/I4210101899 |
| authorships[0].institutions[12].country_code | US |
| authorships[0].institutions[12].display_name | Array BioPharma (United States) |
| authorships[0].institutions[13].id | https://openalex.org/I2948663404 |
| authorships[0].institutions[13].ror | https://ror.org/0385es521 |
| authorships[0].institutions[13].type | company |
| authorships[0].institutions[13].lineage | https://openalex.org/I2948663404 |
| authorships[0].institutions[13].country_code | US |
| authorships[0].institutions[13].display_name | Boston Scientific (United States) |
| authorships[0].institutions[14].id | https://openalex.org/I4210108457 |
| authorships[0].institutions[14].ror | https://ror.org/01sfsq511 |
| authorships[0].institutions[14].type | company |
| authorships[0].institutions[14].lineage | https://openalex.org/I4210108457 |
| authorships[0].institutions[14].country_code | US |
| authorships[0].institutions[14].display_name | Infinity Pharmaceuticals (United States) |
| authorships[0].institutions[15].id | https://openalex.org/I4210103611 |
| authorships[0].institutions[15].ror | https://ror.org/01by01460 |
| authorships[0].institutions[15].type | company |
| authorships[0].institutions[15].lineage | https://openalex.org/I4210103611 |
| authorships[0].institutions[15].country_code | US |
| authorships[0].institutions[15].display_name | Mirati Therapeutics (United States) |
| authorships[0].institutions[16].id | https://openalex.org/I4210124059 |
| authorships[0].institutions[16].ror | https://ror.org/02z43nn16 |
| authorships[0].institutions[16].type | company |
| authorships[0].institutions[16].lineage | https://openalex.org/I4210124059 |
| authorships[0].institutions[16].country_code | US |
| authorships[0].institutions[16].display_name | Taiho Oncology (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Al B. Benson |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Array BioPharma Inc.,, Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and, Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals,, GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc.,, Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd.,, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company,, TheraBionic., research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[1].author.id | https://openalex.org/A5009465403 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3731-0534 |
| authorships[1].author.display_name | Michael I. D’Angelica |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[1].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center; |
| authorships[1].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[1].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Michael I. D’Angelica |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center; |
| authorships[2].author.id | https://openalex.org/A5045494904 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3101-1573 |
| authorships[2].author.display_name | Thomas A. Abrams |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210161994 |
| authorships[2].affiliations[0].raw_affiliation_string | Dana-Farber/Brigham and Women's Cancer Center; |
| authorships[2].institutions[0].id | https://openalex.org/I4210161994 |
| authorships[2].institutions[0].ror | https://ror.org/05rgrbr06 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1283280774, https://openalex.org/I4210117453, https://openalex.org/I4210161994, https://openalex.org/I48633490 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Dana-Farber Brigham Cancer Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Thomas Abrams |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Dana-Farber/Brigham and Women's Cancer Center; |
| authorships[3].author.id | https://openalex.org/A5075432941 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5539-0734 |
| authorships[3].author.display_name | Daniel E. Abbott |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210103341 |
| authorships[3].affiliations[0].raw_affiliation_string | University of Wisconsin Carbone Cancer Center; |
| authorships[3].institutions[0].id | https://openalex.org/I4210103341 |
| authorships[3].institutions[0].ror | https://ror.org/01e4byj08 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2799905417, https://openalex.org/I4210103341, https://openalex.org/I4210132596 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | University of Wisconsin Carbone Cancer Center |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Daniel E. Abbott |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | University of Wisconsin Carbone Cancer Center; |
| authorships[4].author.id | https://openalex.org/A5111217645 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Aijaz Ahmed |
| authorships[4].countries | IN |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2801345345, https://openalex.org/I4390039303 |
| authorships[4].affiliations[0].raw_affiliation_string | Stanford Cancer Institute; |
| authorships[4].institutions[0].id | https://openalex.org/I4390039303 |
| authorships[4].institutions[0].ror | https://ror.org/014qe3j22 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210137306, https://openalex.org/I4390039303, https://openalex.org/I97018004 |
| authorships[4].institutions[0].country_code | |
| authorships[4].institutions[0].display_name | Stanford Cancer Institute |
| authorships[4].institutions[1].id | https://openalex.org/I2801345345 |
| authorships[4].institutions[1].ror | https://ror.org/01tc10z29 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I2801345345 |
| authorships[4].institutions[1].country_code | IN |
| authorships[4].institutions[1].display_name | Cancer Institute (WIA) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Aijaz Ahmed |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Stanford Cancer Institute; |
| authorships[5].author.id | https://openalex.org/A5102089067 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-6569-3931 |
| authorships[5].author.display_name | Daniel A. Anaya |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I3019308854 |
| authorships[5].affiliations[0].raw_affiliation_string | Moffitt Cancer Center; |
| authorships[5].institutions[0].id | https://openalex.org/I3019308854 |
| authorships[5].institutions[0].ror | https://ror.org/01xf75524 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I3019308854 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Moffitt Cancer Center |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Daniel A. Anaya |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Moffitt Cancer Center; |
| authorships[6].author.id | https://openalex.org/A5025711714 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-2363-9072 |
| authorships[6].author.display_name | Robert A. Anders |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210164401 |
| authorships[6].affiliations[0].raw_affiliation_string | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; |
| authorships[6].institutions[0].id | https://openalex.org/I4210164401 |
| authorships[6].institutions[0].ror | https://ror.org/05m5b8x20 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I2799853436, https://openalex.org/I4210164401 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Sidney Kimmel Comprehensive Cancer Center |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Robert Anders |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; |
| authorships[7].author.id | https://openalex.org/A5077137796 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7822-8898 |
| authorships[7].author.display_name | Chandrakanth Are |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I2801647802, https://openalex.org/I4390039344 |
| authorships[7].affiliations[0].raw_affiliation_string | Fred & Pamela Buffett Cancer Center; |
| authorships[7].institutions[0].id | https://openalex.org/I4390039344 |
| authorships[7].institutions[0].ror | https://ror.org/03n63wv08 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I1307117695, https://openalex.org/I4390039344 |
| authorships[7].institutions[0].country_code | |
| authorships[7].institutions[0].display_name | Fred and Pamela Buffett Cancer Center |
| authorships[7].institutions[1].id | https://openalex.org/I2801647802 |
| authorships[7].institutions[1].ror | https://ror.org/04y64sc23 |
| authorships[7].institutions[1].type | nonprofit |
| authorships[7].institutions[1].lineage | https://openalex.org/I2801647802 |
| authorships[7].institutions[1].country_code | US |
| authorships[7].institutions[1].display_name | Susan Thompson Buffett Foundation |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Chandrakanth Are |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Fred & Pamela Buffett Cancer Center; |
| authorships[8].author.id | https://openalex.org/A5041496709 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-6850-2929 |
| authorships[8].author.display_name | Melinda Bachini |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210146809 |
| authorships[8].affiliations[0].raw_affiliation_string | The Cholangiocarcinoma Foundation; |
| authorships[8].institutions[0].id | https://openalex.org/I4210146809 |
| authorships[8].institutions[0].ror | https://ror.org/04fp9z389 |
| authorships[8].institutions[0].type | nonprofit |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210146809 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Cholangiocarcinoma Foundation |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Melinda Bachini |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | The Cholangiocarcinoma Foundation; |
| authorships[9].author.id | https://openalex.org/A5102910163 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | David C. Binder |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210134151, https://openalex.org/I921990950 |
| authorships[9].affiliations[0].raw_affiliation_string | University of Colorado Cancer Center; |
| authorships[9].institutions[0].id | https://openalex.org/I4210134151 |
| authorships[9].institutions[0].ror | https://ror.org/04cqn7d42 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210134151 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | University of Colorado Cancer Center |
| authorships[9].institutions[1].id | https://openalex.org/I921990950 |
| authorships[9].institutions[1].ror | https://ror.org/02hh7en24 |
| authorships[9].institutions[1].type | education |
| authorships[9].institutions[1].lineage | https://openalex.org/I921990950 |
| authorships[9].institutions[1].country_code | US |
| authorships[9].institutions[1].display_name | University of Colorado Denver |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | David Binder |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | University of Colorado Cancer Center; |
| authorships[10].author.id | https://openalex.org/A5018257387 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-2700-2658 |
| authorships[10].author.display_name | Mitesh J. Borad |
| authorships[10].affiliations[0].raw_affiliation_string | Mayo Clinic Comprehensive Cancer Center; |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Mitesh Borad |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Mayo Clinic Comprehensive Cancer Center; |
| authorships[11].author.id | https://openalex.org/A5029813521 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-3906-6811 |
| authorships[11].author.display_name | Christopher L. Bowlus |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210157065, https://openalex.org/I4390039352 |
| authorships[11].affiliations[0].raw_affiliation_string | UC Davis Comprehensive Cancer Center; 13 Vanderbilt-Ingram Cancer Center; |
| authorships[11].institutions[0].id | https://openalex.org/I4390039352 |
| authorships[11].institutions[0].ror | https://ror.org/02kcc1z29 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210160856, https://openalex.org/I4390039352 |
| authorships[11].institutions[0].country_code | |
| authorships[11].institutions[0].display_name | UC Davis Comprehensive Cancer Center |
| authorships[11].institutions[1].id | https://openalex.org/I4210157065 |
| authorships[11].institutions[1].ror | https://ror.org/0552r4b12 |
| authorships[11].institutions[1].type | healthcare |
| authorships[11].institutions[1].lineage | https://openalex.org/I145608581, https://openalex.org/I4210101935, https://openalex.org/I4210157065 |
| authorships[11].institutions[1].country_code | US |
| authorships[11].institutions[1].display_name | Sylvester Comprehensive Cancer Center |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Christopher Bowlus |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | UC Davis Comprehensive Cancer Center; 13 Vanderbilt-Ingram Cancer Center; |
| authorships[12].author.id | https://openalex.org/A5018663815 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-0533-2883 |
| authorships[12].author.display_name | Daniel B. Brown |
| authorships[12].countries | BE, CH, CN, DE, GB, IN, JP, US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210101899 |
| authorships[12].affiliations[0].raw_affiliation_string | Array BioPharma Inc., |
| authorships[12].affiliations[1].institution_ids | https://openalex.org/I137982388, https://openalex.org/I4210099842, https://openalex.org/I4210103611 |
| authorships[12].affiliations[1].raw_affiliation_string | GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc., |
| authorships[12].affiliations[2].institution_ids | https://openalex.org/I137982388, https://openalex.org/I189718659, https://openalex.org/I4210108457 |
| authorships[12].affiliations[2].raw_affiliation_string | Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals, |
| authorships[12].affiliations[3].raw_affiliation_string | TheraBionic. |
| authorships[12].affiliations[4].institution_ids | https://openalex.org/I189718659, https://openalex.org/I4210117523, https://openalex.org/I4210120269, https://openalex.org/I4210124059 |
| authorships[12].affiliations[4].raw_affiliation_string | Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd., |
| authorships[12].affiliations[5].raw_affiliation_string | Comprehensive Cancer Center of Northwestern University; |
| authorships[12].affiliations[6].institution_ids | https://openalex.org/I157075465 |
| authorships[12].affiliations[6].raw_affiliation_string | ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company, |
| authorships[12].affiliations[7].institution_ids | https://openalex.org/I1283582996, https://openalex.org/I2948663404, https://openalex.org/I4210088994, https://openalex.org/I4210103611 |
| authorships[12].affiliations[7].raw_affiliation_string | Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and |
| authorships[12].affiliations[8].institution_ids | https://openalex.org/I1320553840, https://openalex.org/I2948539688, https://openalex.org/I4210119928 |
| authorships[12].affiliations[8].raw_affiliation_string | research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[12].institutions[0].id | https://openalex.org/I137982388 |
| authorships[12].institutions[0].ror | https://ror.org/04yzcpd71 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[12].institutions[0].country_code | BE |
| authorships[12].institutions[0].display_name | Janssen (Belgium) |
| authorships[12].institutions[1].id | https://openalex.org/I1283582996 |
| authorships[12].institutions[1].ror | https://ror.org/02f9zrr09 |
| authorships[12].institutions[1].type | company |
| authorships[12].institutions[1].lineage | https://openalex.org/I1283582996 |
| authorships[12].institutions[1].country_code | CH |
| authorships[12].institutions[1].display_name | Novartis (Switzerland) |
| authorships[12].institutions[2].id | https://openalex.org/I4210088994 |
| authorships[12].institutions[2].ror | https://ror.org/008h8bh21 |
| authorships[12].institutions[2].type | company |
| authorships[12].institutions[2].lineage | https://openalex.org/I142395110, https://openalex.org/I4210088994 |
| authorships[12].institutions[2].country_code | CN |
| authorships[12].institutions[2].display_name | Astellas Pharma (China) |
| authorships[12].institutions[3].id | https://openalex.org/I157075465 |
| authorships[12].institutions[3].ror | https://ror.org/032hfv632 |
| authorships[12].institutions[3].type | company |
| authorships[12].institutions[3].lineage | https://openalex.org/I157075465, https://openalex.org/I4210091812 |
| authorships[12].institutions[3].country_code | DE |
| authorships[12].institutions[3].display_name | Bristol-Myers Squibb (Germany) |
| authorships[12].institutions[4].id | https://openalex.org/I189718659 |
| authorships[12].institutions[4].ror | https://ror.org/04x4v8p40 |
| authorships[12].institutions[4].type | company |
| authorships[12].institutions[4].lineage | https://openalex.org/I180857899, https://openalex.org/I189718659 |
| authorships[12].institutions[4].country_code | GB |
| authorships[12].institutions[4].display_name | Pfizer (United Kingdom) |
| authorships[12].institutions[5].id | https://openalex.org/I4210117523 |
| authorships[12].institutions[5].ror | https://ror.org/01w6gjq94 |
| authorships[12].institutions[5].type | company |
| authorships[12].institutions[5].lineage | https://openalex.org/I2250650973, https://openalex.org/I4210117523 |
| authorships[12].institutions[5].country_code | GB |
| authorships[12].institutions[5].display_name | Samsung (United Kingdom) |
| authorships[12].institutions[6].id | https://openalex.org/I4210099842 |
| authorships[12].institutions[6].ror | https://ror.org/01tvt4d48 |
| authorships[12].institutions[6].type | company |
| authorships[12].institutions[6].lineage | https://openalex.org/I188950975, https://openalex.org/I4210099842 |
| authorships[12].institutions[6].country_code | IN |
| authorships[12].institutions[6].display_name | GlaxoSmithKline (India) |
| authorships[12].institutions[7].id | https://openalex.org/I4210120269 |
| authorships[12].institutions[7].ror | https://ror.org/02v50dx14 |
| authorships[12].institutions[7].type | company |
| authorships[12].institutions[7].lineage | https://openalex.org/I4210120269 |
| authorships[12].institutions[7].country_code | JP |
| authorships[12].institutions[7].display_name | Taiho Pharmaceutical (Japan) |
| authorships[12].institutions[8].id | https://openalex.org/I2948539688 |
| authorships[12].institutions[8].ror | https://ror.org/02g5p4n58 |
| authorships[12].institutions[8].type | company |
| authorships[12].institutions[8].lineage | https://openalex.org/I2948539688 |
| authorships[12].institutions[8].country_code | US |
| authorships[12].institutions[8].display_name | AbbVie (United States) |
| authorships[12].institutions[9].id | https://openalex.org/I1320553840 |
| authorships[12].institutions[9].ror | https://ror.org/03g03ge92 |
| authorships[12].institutions[9].type | company |
| authorships[12].institutions[9].lineage | https://openalex.org/I1320553840 |
| authorships[12].institutions[9].country_code | US |
| authorships[12].institutions[9].display_name | Amgen (United States) |
| authorships[12].institutions[10].id | https://openalex.org/I4210119928 |
| authorships[12].institutions[10].ror | https://ror.org/02c7apg81 |
| authorships[12].institutions[10].type | company |
| authorships[12].institutions[10].lineage | https://openalex.org/I4210119928 |
| authorships[12].institutions[10].country_code | US |
| authorships[12].institutions[10].display_name | Apexigen (United States) |
| authorships[12].institutions[11].id | https://openalex.org/I4210101899 |
| authorships[12].institutions[11].ror | https://ror.org/018axtd57 |
| authorships[12].institutions[11].type | company |
| authorships[12].institutions[11].lineage | https://openalex.org/I4210101899 |
| authorships[12].institutions[11].country_code | US |
| authorships[12].institutions[11].display_name | Array BioPharma (United States) |
| authorships[12].institutions[12].id | https://openalex.org/I2948663404 |
| authorships[12].institutions[12].ror | https://ror.org/0385es521 |
| authorships[12].institutions[12].type | company |
| authorships[12].institutions[12].lineage | https://openalex.org/I2948663404 |
| authorships[12].institutions[12].country_code | US |
| authorships[12].institutions[12].display_name | Boston Scientific (United States) |
| authorships[12].institutions[13].id | https://openalex.org/I4210108457 |
| authorships[12].institutions[13].ror | https://ror.org/01sfsq511 |
| authorships[12].institutions[13].type | company |
| authorships[12].institutions[13].lineage | https://openalex.org/I4210108457 |
| authorships[12].institutions[13].country_code | US |
| authorships[12].institutions[13].display_name | Infinity Pharmaceuticals (United States) |
| authorships[12].institutions[14].id | https://openalex.org/I4210103611 |
| authorships[12].institutions[14].ror | https://ror.org/01by01460 |
| authorships[12].institutions[14].type | company |
| authorships[12].institutions[14].lineage | https://openalex.org/I4210103611 |
| authorships[12].institutions[14].country_code | US |
| authorships[12].institutions[14].display_name | Mirati Therapeutics (United States) |
| authorships[12].institutions[15].id | https://openalex.org/I4210124059 |
| authorships[12].institutions[15].ror | https://ror.org/02z43nn16 |
| authorships[12].institutions[15].type | company |
| authorships[12].institutions[15].lineage | https://openalex.org/I4210124059 |
| authorships[12].institutions[15].country_code | US |
| authorships[12].institutions[15].display_name | Taiho Oncology (United States) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Daniel Brown |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Array BioPharma Inc.,, Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and, Comprehensive Cancer Center of Northwestern University;, Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals,, GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc.,, Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd.,, ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company,, TheraBionic., research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[13].author.id | https://openalex.org/A5014017772 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-4351-9940 |
| authorships[13].author.display_name | Adam M. Burgoyne |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I1289437631 |
| authorships[13].affiliations[0].raw_affiliation_string | UC San Diego Moores Cancer Center; 15 Fox Chase Cancer Center; |
| authorships[13].institutions[0].id | https://openalex.org/I1289437631 |
| authorships[13].institutions[0].ror | https://ror.org/0567t7073 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I1289437631, https://openalex.org/I4210122924 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Fox Chase Cancer Center |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Adam Burgoyne |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | UC San Diego Moores Cancer Center; 15 Fox Chase Cancer Center; |
| authorships[14].author.id | https://openalex.org/A5108806413 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-0771-3727 |
| authorships[14].author.display_name | Jason Castellanos |
| authorships[14].countries | BE, CH, CN, DE, GB, IN, JP, US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I1320553840, https://openalex.org/I2948539688, https://openalex.org/I4210119928 |
| authorships[14].affiliations[0].raw_affiliation_string | research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[14].affiliations[1].institution_ids | https://openalex.org/I1283582996, https://openalex.org/I2948663404, https://openalex.org/I4210088994, https://openalex.org/I4210103611 |
| authorships[14].affiliations[1].raw_affiliation_string | Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and |
| authorships[14].affiliations[2].raw_affiliation_string | TheraBionic. |
| authorships[14].affiliations[3].institution_ids | https://openalex.org/I4210101899 |
| authorships[14].affiliations[3].raw_affiliation_string | Array BioPharma Inc., |
| authorships[14].affiliations[4].raw_affiliation_string | Comprehensive Cancer Center of Northwestern University; |
| authorships[14].affiliations[5].institution_ids | https://openalex.org/I157075465 |
| authorships[14].affiliations[5].raw_affiliation_string | ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company, |
| authorships[14].affiliations[6].institution_ids | https://openalex.org/I189718659, https://openalex.org/I4210117523, https://openalex.org/I4210120269, https://openalex.org/I4210124059 |
| authorships[14].affiliations[6].raw_affiliation_string | Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd., |
| authorships[14].affiliations[7].institution_ids | https://openalex.org/I137982388, https://openalex.org/I189718659, https://openalex.org/I4210108457 |
| authorships[14].affiliations[7].raw_affiliation_string | Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals, |
| authorships[14].affiliations[8].institution_ids | https://openalex.org/I137982388, https://openalex.org/I4210099842, https://openalex.org/I4210103611 |
| authorships[14].affiliations[8].raw_affiliation_string | GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc., |
| authorships[14].institutions[0].id | https://openalex.org/I137982388 |
| authorships[14].institutions[0].ror | https://ror.org/04yzcpd71 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[14].institutions[0].country_code | BE |
| authorships[14].institutions[0].display_name | Janssen (Belgium) |
| authorships[14].institutions[1].id | https://openalex.org/I1283582996 |
| authorships[14].institutions[1].ror | https://ror.org/02f9zrr09 |
| authorships[14].institutions[1].type | company |
| authorships[14].institutions[1].lineage | https://openalex.org/I1283582996 |
| authorships[14].institutions[1].country_code | CH |
| authorships[14].institutions[1].display_name | Novartis (Switzerland) |
| authorships[14].institutions[2].id | https://openalex.org/I4210088994 |
| authorships[14].institutions[2].ror | https://ror.org/008h8bh21 |
| authorships[14].institutions[2].type | company |
| authorships[14].institutions[2].lineage | https://openalex.org/I142395110, https://openalex.org/I4210088994 |
| authorships[14].institutions[2].country_code | CN |
| authorships[14].institutions[2].display_name | Astellas Pharma (China) |
| authorships[14].institutions[3].id | https://openalex.org/I157075465 |
| authorships[14].institutions[3].ror | https://ror.org/032hfv632 |
| authorships[14].institutions[3].type | company |
| authorships[14].institutions[3].lineage | https://openalex.org/I157075465, https://openalex.org/I4210091812 |
| authorships[14].institutions[3].country_code | DE |
| authorships[14].institutions[3].display_name | Bristol-Myers Squibb (Germany) |
| authorships[14].institutions[4].id | https://openalex.org/I189718659 |
| authorships[14].institutions[4].ror | https://ror.org/04x4v8p40 |
| authorships[14].institutions[4].type | company |
| authorships[14].institutions[4].lineage | https://openalex.org/I180857899, https://openalex.org/I189718659 |
| authorships[14].institutions[4].country_code | GB |
| authorships[14].institutions[4].display_name | Pfizer (United Kingdom) |
| authorships[14].institutions[5].id | https://openalex.org/I4210117523 |
| authorships[14].institutions[5].ror | https://ror.org/01w6gjq94 |
| authorships[14].institutions[5].type | company |
| authorships[14].institutions[5].lineage | https://openalex.org/I2250650973, https://openalex.org/I4210117523 |
| authorships[14].institutions[5].country_code | GB |
| authorships[14].institutions[5].display_name | Samsung (United Kingdom) |
| authorships[14].institutions[6].id | https://openalex.org/I4210099842 |
| authorships[14].institutions[6].ror | https://ror.org/01tvt4d48 |
| authorships[14].institutions[6].type | company |
| authorships[14].institutions[6].lineage | https://openalex.org/I188950975, https://openalex.org/I4210099842 |
| authorships[14].institutions[6].country_code | IN |
| authorships[14].institutions[6].display_name | GlaxoSmithKline (India) |
| authorships[14].institutions[7].id | https://openalex.org/I4210120269 |
| authorships[14].institutions[7].ror | https://ror.org/02v50dx14 |
| authorships[14].institutions[7].type | company |
| authorships[14].institutions[7].lineage | https://openalex.org/I4210120269 |
| authorships[14].institutions[7].country_code | JP |
| authorships[14].institutions[7].display_name | Taiho Pharmaceutical (Japan) |
| authorships[14].institutions[8].id | https://openalex.org/I2948539688 |
| authorships[14].institutions[8].ror | https://ror.org/02g5p4n58 |
| authorships[14].institutions[8].type | company |
| authorships[14].institutions[8].lineage | https://openalex.org/I2948539688 |
| authorships[14].institutions[8].country_code | US |
| authorships[14].institutions[8].display_name | AbbVie (United States) |
| authorships[14].institutions[9].id | https://openalex.org/I1320553840 |
| authorships[14].institutions[9].ror | https://ror.org/03g03ge92 |
| authorships[14].institutions[9].type | company |
| authorships[14].institutions[9].lineage | https://openalex.org/I1320553840 |
| authorships[14].institutions[9].country_code | US |
| authorships[14].institutions[9].display_name | Amgen (United States) |
| authorships[14].institutions[10].id | https://openalex.org/I4210119928 |
| authorships[14].institutions[10].ror | https://ror.org/02c7apg81 |
| authorships[14].institutions[10].type | company |
| authorships[14].institutions[10].lineage | https://openalex.org/I4210119928 |
| authorships[14].institutions[10].country_code | US |
| authorships[14].institutions[10].display_name | Apexigen (United States) |
| authorships[14].institutions[11].id | https://openalex.org/I4210101899 |
| authorships[14].institutions[11].ror | https://ror.org/018axtd57 |
| authorships[14].institutions[11].type | company |
| authorships[14].institutions[11].lineage | https://openalex.org/I4210101899 |
| authorships[14].institutions[11].country_code | US |
| authorships[14].institutions[11].display_name | Array BioPharma (United States) |
| authorships[14].institutions[12].id | https://openalex.org/I2948663404 |
| authorships[14].institutions[12].ror | https://ror.org/0385es521 |
| authorships[14].institutions[12].type | company |
| authorships[14].institutions[12].lineage | https://openalex.org/I2948663404 |
| authorships[14].institutions[12].country_code | US |
| authorships[14].institutions[12].display_name | Boston Scientific (United States) |
| authorships[14].institutions[13].id | https://openalex.org/I4210108457 |
| authorships[14].institutions[13].ror | https://ror.org/01sfsq511 |
| authorships[14].institutions[13].type | company |
| authorships[14].institutions[13].lineage | https://openalex.org/I4210108457 |
| authorships[14].institutions[13].country_code | US |
| authorships[14].institutions[13].display_name | Infinity Pharmaceuticals (United States) |
| authorships[14].institutions[14].id | https://openalex.org/I4210103611 |
| authorships[14].institutions[14].ror | https://ror.org/01by01460 |
| authorships[14].institutions[14].type | company |
| authorships[14].institutions[14].lineage | https://openalex.org/I4210103611 |
| authorships[14].institutions[14].country_code | US |
| authorships[14].institutions[14].display_name | Mirati Therapeutics (United States) |
| authorships[14].institutions[15].id | https://openalex.org/I4210124059 |
| authorships[14].institutions[15].ror | https://ror.org/02z43nn16 |
| authorships[14].institutions[15].type | company |
| authorships[14].institutions[15].lineage | https://openalex.org/I4210124059 |
| authorships[14].institutions[15].country_code | US |
| authorships[14].institutions[15].display_name | Taiho Oncology (United States) |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Jason Castellanos |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Array BioPharma Inc.,, Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and, Comprehensive Cancer Center of Northwestern University;, Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals,, GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc.,, Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd.,, ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company,, TheraBionic., research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[15].author.id | https://openalex.org/A5018049008 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-4744-4288 |
| authorships[15].author.display_name | Prabhleen Chahal |
| authorships[15].countries | IN, US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I1316902750, https://openalex.org/I2801345345, https://openalex.org/I4210119077 |
| authorships[15].affiliations[0].raw_affiliation_string | Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; |
| authorships[15].institutions[0].id | https://openalex.org/I2801345345 |
| authorships[15].institutions[0].ror | https://ror.org/01tc10z29 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I2801345345 |
| authorships[15].institutions[0].country_code | IN |
| authorships[15].institutions[0].display_name | Cancer Institute (WIA) |
| authorships[15].institutions[1].id | https://openalex.org/I1316902750 |
| authorships[15].institutions[1].ror | https://ror.org/03xjacd83 |
| authorships[15].institutions[1].type | healthcare |
| authorships[15].institutions[1].lineage | https://openalex.org/I1316902750 |
| authorships[15].institutions[1].country_code | US |
| authorships[15].institutions[1].display_name | Cleveland Clinic |
| authorships[15].institutions[2].id | https://openalex.org/I4210119077 |
| authorships[15].institutions[2].ror | https://ror.org/02kb97560 |
| authorships[15].institutions[2].type | healthcare |
| authorships[15].institutions[2].lineage | https://openalex.org/I2799343972, https://openalex.org/I4210119077 |
| authorships[15].institutions[2].country_code | US |
| authorships[15].institutions[2].display_name | University Hospitals Seidman Cancer Center |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Prabhleen Chahal |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; |
| authorships[16].author.id | https://openalex.org/A5057140415 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-2373-8433 |
| authorships[16].author.display_name | Jordan M. Cloyd |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I2799885155 |
| authorships[16].affiliations[0].raw_affiliation_string | The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute; |
| authorships[16].institutions[0].id | https://openalex.org/I2799885155 |
| authorships[16].institutions[0].ror | https://ror.org/028t46f04 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I2799885155 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Jordan Cloyd |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute; |
| authorships[17].author.id | https://openalex.org/A5090827566 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-1477-8468 |
| authorships[17].author.display_name | Anne M. Covey |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[17].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center; |
| authorships[17].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[17].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Anne M. Covey |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center; |
| authorships[18].author.id | https://openalex.org/A5088291412 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-5796-0542 |
| authorships[18].author.display_name | Evan S. Glazer |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I160606119 |
| authorships[18].affiliations[0].raw_affiliation_string | The University of Tennessee Health Science Center; |
| authorships[18].institutions[0].id | https://openalex.org/I160606119 |
| authorships[18].institutions[0].ror | https://ror.org/0011qv509 |
| authorships[18].institutions[0].type | education |
| authorships[18].institutions[0].lineage | https://openalex.org/I160606119 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | University of Tennessee Health Science Center |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Evan S. Glazer |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | The University of Tennessee Health Science Center; |
| authorships[19].author.id | https://openalex.org/A5060050760 |
| authorships[19].author.orcid | https://orcid.org/0000-0001-7087-3585 |
| authorships[19].author.display_name | William G. Hawkins |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I1299725459, https://openalex.org/I4210102777 |
| authorships[19].affiliations[0].raw_affiliation_string | Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 20 Roswell Park Comprehensive Cancer Center; |
| authorships[19].institutions[0].id | https://openalex.org/I1299725459 |
| authorships[19].institutions[0].ror | https://ror.org/04wyvkr12 |
| authorships[19].institutions[0].type | healthcare |
| authorships[19].institutions[0].lineage | https://openalex.org/I1299725459, https://openalex.org/I1328499231 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | Barnes-Jewish Hospital |
| authorships[19].institutions[1].id | https://openalex.org/I4210102777 |
| authorships[19].institutions[1].ror | https://ror.org/018s10n18 |
| authorships[19].institutions[1].type | healthcare |
| authorships[19].institutions[1].lineage | https://openalex.org/I4210102777 |
| authorships[19].institutions[1].country_code | US |
| authorships[19].institutions[1].display_name | Jewish Hospital |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | William G. Hawkins |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 20 Roswell Park Comprehensive Cancer Center; |
| authorships[20].author.id | https://openalex.org/A5055725897 |
| authorships[20].author.orcid | https://orcid.org/0000-0003-3643-8621 |
| authorships[20].author.display_name | Renuka Iyer |
| authorships[20].countries | BE, CH, CN, DE, GB, IN, JP, US |
| authorships[20].affiliations[0].raw_affiliation_string | TheraBionic. |
| authorships[20].affiliations[1].institution_ids | https://openalex.org/I4210101899 |
| authorships[20].affiliations[1].raw_affiliation_string | Array BioPharma Inc., |
| authorships[20].affiliations[2].institution_ids | https://openalex.org/I1320553840, https://openalex.org/I2948539688, https://openalex.org/I4210119928 |
| authorships[20].affiliations[2].raw_affiliation_string | research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[20].affiliations[3].institution_ids | https://openalex.org/I137982388, https://openalex.org/I4210099842, https://openalex.org/I4210103611 |
| authorships[20].affiliations[3].raw_affiliation_string | GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc., |
| authorships[20].affiliations[4].raw_affiliation_string | Comprehensive Cancer Center of Northwestern University; |
| authorships[20].affiliations[5].institution_ids | https://openalex.org/I157075465 |
| authorships[20].affiliations[5].raw_affiliation_string | ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company, |
| authorships[20].affiliations[6].institution_ids | https://openalex.org/I1283582996, https://openalex.org/I2948663404, https://openalex.org/I4210088994, https://openalex.org/I4210103611 |
| authorships[20].affiliations[6].raw_affiliation_string | Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and |
| authorships[20].affiliations[7].institution_ids | https://openalex.org/I189718659, https://openalex.org/I4210117523, https://openalex.org/I4210120269, https://openalex.org/I4210124059 |
| authorships[20].affiliations[7].raw_affiliation_string | Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd., |
| authorships[20].affiliations[8].institution_ids | https://openalex.org/I137982388, https://openalex.org/I189718659, https://openalex.org/I4210108457 |
| authorships[20].affiliations[8].raw_affiliation_string | Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals, |
| authorships[20].institutions[0].id | https://openalex.org/I137982388 |
| authorships[20].institutions[0].ror | https://ror.org/04yzcpd71 |
| authorships[20].institutions[0].type | company |
| authorships[20].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[20].institutions[0].country_code | BE |
| authorships[20].institutions[0].display_name | Janssen (Belgium) |
| authorships[20].institutions[1].id | https://openalex.org/I1283582996 |
| authorships[20].institutions[1].ror | https://ror.org/02f9zrr09 |
| authorships[20].institutions[1].type | company |
| authorships[20].institutions[1].lineage | https://openalex.org/I1283582996 |
| authorships[20].institutions[1].country_code | CH |
| authorships[20].institutions[1].display_name | Novartis (Switzerland) |
| authorships[20].institutions[2].id | https://openalex.org/I4210088994 |
| authorships[20].institutions[2].ror | https://ror.org/008h8bh21 |
| authorships[20].institutions[2].type | company |
| authorships[20].institutions[2].lineage | https://openalex.org/I142395110, https://openalex.org/I4210088994 |
| authorships[20].institutions[2].country_code | CN |
| authorships[20].institutions[2].display_name | Astellas Pharma (China) |
| authorships[20].institutions[3].id | https://openalex.org/I157075465 |
| authorships[20].institutions[3].ror | https://ror.org/032hfv632 |
| authorships[20].institutions[3].type | company |
| authorships[20].institutions[3].lineage | https://openalex.org/I157075465, https://openalex.org/I4210091812 |
| authorships[20].institutions[3].country_code | DE |
| authorships[20].institutions[3].display_name | Bristol-Myers Squibb (Germany) |
| authorships[20].institutions[4].id | https://openalex.org/I189718659 |
| authorships[20].institutions[4].ror | https://ror.org/04x4v8p40 |
| authorships[20].institutions[4].type | company |
| authorships[20].institutions[4].lineage | https://openalex.org/I180857899, https://openalex.org/I189718659 |
| authorships[20].institutions[4].country_code | GB |
| authorships[20].institutions[4].display_name | Pfizer (United Kingdom) |
| authorships[20].institutions[5].id | https://openalex.org/I4210117523 |
| authorships[20].institutions[5].ror | https://ror.org/01w6gjq94 |
| authorships[20].institutions[5].type | company |
| authorships[20].institutions[5].lineage | https://openalex.org/I2250650973, https://openalex.org/I4210117523 |
| authorships[20].institutions[5].country_code | GB |
| authorships[20].institutions[5].display_name | Samsung (United Kingdom) |
| authorships[20].institutions[6].id | https://openalex.org/I4210099842 |
| authorships[20].institutions[6].ror | https://ror.org/01tvt4d48 |
| authorships[20].institutions[6].type | company |
| authorships[20].institutions[6].lineage | https://openalex.org/I188950975, https://openalex.org/I4210099842 |
| authorships[20].institutions[6].country_code | IN |
| authorships[20].institutions[6].display_name | GlaxoSmithKline (India) |
| authorships[20].institutions[7].id | https://openalex.org/I4210120269 |
| authorships[20].institutions[7].ror | https://ror.org/02v50dx14 |
| authorships[20].institutions[7].type | company |
| authorships[20].institutions[7].lineage | https://openalex.org/I4210120269 |
| authorships[20].institutions[7].country_code | JP |
| authorships[20].institutions[7].display_name | Taiho Pharmaceutical (Japan) |
| authorships[20].institutions[8].id | https://openalex.org/I2948539688 |
| authorships[20].institutions[8].ror | https://ror.org/02g5p4n58 |
| authorships[20].institutions[8].type | company |
| authorships[20].institutions[8].lineage | https://openalex.org/I2948539688 |
| authorships[20].institutions[8].country_code | US |
| authorships[20].institutions[8].display_name | AbbVie (United States) |
| authorships[20].institutions[9].id | https://openalex.org/I1320553840 |
| authorships[20].institutions[9].ror | https://ror.org/03g03ge92 |
| authorships[20].institutions[9].type | company |
| authorships[20].institutions[9].lineage | https://openalex.org/I1320553840 |
| authorships[20].institutions[9].country_code | US |
| authorships[20].institutions[9].display_name | Amgen (United States) |
| authorships[20].institutions[10].id | https://openalex.org/I4210119928 |
| authorships[20].institutions[10].ror | https://ror.org/02c7apg81 |
| authorships[20].institutions[10].type | company |
| authorships[20].institutions[10].lineage | https://openalex.org/I4210119928 |
| authorships[20].institutions[10].country_code | US |
| authorships[20].institutions[10].display_name | Apexigen (United States) |
| authorships[20].institutions[11].id | https://openalex.org/I4210101899 |
| authorships[20].institutions[11].ror | https://ror.org/018axtd57 |
| authorships[20].institutions[11].type | company |
| authorships[20].institutions[11].lineage | https://openalex.org/I4210101899 |
| authorships[20].institutions[11].country_code | US |
| authorships[20].institutions[11].display_name | Array BioPharma (United States) |
| authorships[20].institutions[12].id | https://openalex.org/I2948663404 |
| authorships[20].institutions[12].ror | https://ror.org/0385es521 |
| authorships[20].institutions[12].type | company |
| authorships[20].institutions[12].lineage | https://openalex.org/I2948663404 |
| authorships[20].institutions[12].country_code | US |
| authorships[20].institutions[12].display_name | Boston Scientific (United States) |
| authorships[20].institutions[13].id | https://openalex.org/I4210108457 |
| authorships[20].institutions[13].ror | https://ror.org/01sfsq511 |
| authorships[20].institutions[13].type | company |
| authorships[20].institutions[13].lineage | https://openalex.org/I4210108457 |
| authorships[20].institutions[13].country_code | US |
| authorships[20].institutions[13].display_name | Infinity Pharmaceuticals (United States) |
| authorships[20].institutions[14].id | https://openalex.org/I4210103611 |
| authorships[20].institutions[14].ror | https://ror.org/01by01460 |
| authorships[20].institutions[14].type | company |
| authorships[20].institutions[14].lineage | https://openalex.org/I4210103611 |
| authorships[20].institutions[14].country_code | US |
| authorships[20].institutions[14].display_name | Mirati Therapeutics (United States) |
| authorships[20].institutions[15].id | https://openalex.org/I4210124059 |
| authorships[20].institutions[15].ror | https://ror.org/02z43nn16 |
| authorships[20].institutions[15].type | company |
| authorships[20].institutions[15].lineage | https://openalex.org/I4210124059 |
| authorships[20].institutions[15].country_code | US |
| authorships[20].institutions[15].display_name | Taiho Oncology (United States) |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Renuka Iyer |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Array BioPharma Inc.,, Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and, Comprehensive Cancer Center of Northwestern University;, Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals,, GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc.,, Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd.,, ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company,, TheraBionic., research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[21].author.id | https://openalex.org/A5000425500 |
| authorships[21].author.orcid | https://orcid.org/0000-0003-2912-8422 |
| authorships[21].author.display_name | Rojymon Jacob |
| authorships[21].countries | US |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I4210134151, https://openalex.org/I4390039376, https://openalex.org/I921990950 |
| authorships[21].affiliations[0].raw_affiliation_string | O'Neal Comprehensive Cancer Center at UAB; |
| authorships[21].institutions[0].id | https://openalex.org/I4390039376 |
| authorships[21].institutions[0].ror | https://ror.org/03j18km61 |
| authorships[21].institutions[0].type | healthcare |
| authorships[21].institutions[0].lineage | https://openalex.org/I4390039250, https://openalex.org/I4390039376 |
| authorships[21].institutions[0].country_code | |
| authorships[21].institutions[0].display_name | O'Neal Comprehensive Cancer Center |
| authorships[21].institutions[1].id | https://openalex.org/I4210134151 |
| authorships[21].institutions[1].ror | https://ror.org/04cqn7d42 |
| authorships[21].institutions[1].type | healthcare |
| authorships[21].institutions[1].lineage | https://openalex.org/I4210134151 |
| authorships[21].institutions[1].country_code | US |
| authorships[21].institutions[1].display_name | University of Colorado Cancer Center |
| authorships[21].institutions[2].id | https://openalex.org/I921990950 |
| authorships[21].institutions[2].ror | https://ror.org/02hh7en24 |
| authorships[21].institutions[2].type | education |
| authorships[21].institutions[2].lineage | https://openalex.org/I921990950 |
| authorships[21].institutions[2].country_code | US |
| authorships[21].institutions[2].display_name | University of Colorado Denver |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Rojymon Jacob |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | O'Neal Comprehensive Cancer Center at UAB; |
| authorships[22].author.id | https://openalex.org/A5084339424 |
| authorships[22].author.orcid | https://orcid.org/0000-0001-8669-7774 |
| authorships[22].author.display_name | Lawrence J. Jennings |
| authorships[22].countries | BE, CH, CN, DE, GB, IN, JP, US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I4390039227 |
| authorships[22].affiliations[0].raw_affiliation_string | Robert H. Lurie Comprehensive Cancer Center of Northwestern University |
| authorships[22].affiliations[1].institution_ids | https://openalex.org/I4210101899 |
| authorships[22].affiliations[1].raw_affiliation_string | Array BioPharma Inc., |
| authorships[22].affiliations[2].institution_ids | https://openalex.org/I1283582996, https://openalex.org/I2948663404, https://openalex.org/I4210088994, https://openalex.org/I4210103611 |
| authorships[22].affiliations[2].raw_affiliation_string | Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and |
| authorships[22].affiliations[3].institution_ids | https://openalex.org/I1320553840, https://openalex.org/I2948539688, https://openalex.org/I4210119928 |
| authorships[22].affiliations[3].raw_affiliation_string | research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[22].affiliations[4].institution_ids | https://openalex.org/I137982388, https://openalex.org/I4210099842, https://openalex.org/I4210103611 |
| authorships[22].affiliations[4].raw_affiliation_string | GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc., |
| authorships[22].affiliations[5].institution_ids | https://openalex.org/I137982388, https://openalex.org/I189718659, https://openalex.org/I4210108457 |
| authorships[22].affiliations[5].raw_affiliation_string | Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals, |
| authorships[22].affiliations[6].raw_affiliation_string | TheraBionic. |
| authorships[22].affiliations[7].institution_ids | https://openalex.org/I189718659, https://openalex.org/I4210117523, https://openalex.org/I4210120269, https://openalex.org/I4210124059 |
| authorships[22].affiliations[7].raw_affiliation_string | Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd., |
| authorships[22].affiliations[8].institution_ids | https://openalex.org/I157075465 |
| authorships[22].affiliations[8].raw_affiliation_string | ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company, |
| authorships[22].institutions[0].id | https://openalex.org/I4390039227 |
| authorships[22].institutions[0].ror | https://ror.org/02p4far57 |
| authorships[22].institutions[0].type | healthcare |
| authorships[22].institutions[0].lineage | https://openalex.org/I4210147348, https://openalex.org/I4390039227 |
| authorships[22].institutions[0].country_code | |
| authorships[22].institutions[0].display_name | Robert H. Lurie Comprehensive Cancer Center of Northwestern University |
| authorships[22].institutions[1].id | https://openalex.org/I137982388 |
| authorships[22].institutions[1].ror | https://ror.org/04yzcpd71 |
| authorships[22].institutions[1].type | company |
| authorships[22].institutions[1].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[22].institutions[1].country_code | BE |
| authorships[22].institutions[1].display_name | Janssen (Belgium) |
| authorships[22].institutions[2].id | https://openalex.org/I1283582996 |
| authorships[22].institutions[2].ror | https://ror.org/02f9zrr09 |
| authorships[22].institutions[2].type | company |
| authorships[22].institutions[2].lineage | https://openalex.org/I1283582996 |
| authorships[22].institutions[2].country_code | CH |
| authorships[22].institutions[2].display_name | Novartis (Switzerland) |
| authorships[22].institutions[3].id | https://openalex.org/I4210088994 |
| authorships[22].institutions[3].ror | https://ror.org/008h8bh21 |
| authorships[22].institutions[3].type | company |
| authorships[22].institutions[3].lineage | https://openalex.org/I142395110, https://openalex.org/I4210088994 |
| authorships[22].institutions[3].country_code | CN |
| authorships[22].institutions[3].display_name | Astellas Pharma (China) |
| authorships[22].institutions[4].id | https://openalex.org/I157075465 |
| authorships[22].institutions[4].ror | https://ror.org/032hfv632 |
| authorships[22].institutions[4].type | company |
| authorships[22].institutions[4].lineage | https://openalex.org/I157075465, https://openalex.org/I4210091812 |
| authorships[22].institutions[4].country_code | DE |
| authorships[22].institutions[4].display_name | Bristol-Myers Squibb (Germany) |
| authorships[22].institutions[5].id | https://openalex.org/I189718659 |
| authorships[22].institutions[5].ror | https://ror.org/04x4v8p40 |
| authorships[22].institutions[5].type | company |
| authorships[22].institutions[5].lineage | https://openalex.org/I180857899, https://openalex.org/I189718659 |
| authorships[22].institutions[5].country_code | GB |
| authorships[22].institutions[5].display_name | Pfizer (United Kingdom) |
| authorships[22].institutions[6].id | https://openalex.org/I4210117523 |
| authorships[22].institutions[6].ror | https://ror.org/01w6gjq94 |
| authorships[22].institutions[6].type | company |
| authorships[22].institutions[6].lineage | https://openalex.org/I2250650973, https://openalex.org/I4210117523 |
| authorships[22].institutions[6].country_code | GB |
| authorships[22].institutions[6].display_name | Samsung (United Kingdom) |
| authorships[22].institutions[7].id | https://openalex.org/I4210099842 |
| authorships[22].institutions[7].ror | https://ror.org/01tvt4d48 |
| authorships[22].institutions[7].type | company |
| authorships[22].institutions[7].lineage | https://openalex.org/I188950975, https://openalex.org/I4210099842 |
| authorships[22].institutions[7].country_code | IN |
| authorships[22].institutions[7].display_name | GlaxoSmithKline (India) |
| authorships[22].institutions[8].id | https://openalex.org/I4210120269 |
| authorships[22].institutions[8].ror | https://ror.org/02v50dx14 |
| authorships[22].institutions[8].type | company |
| authorships[22].institutions[8].lineage | https://openalex.org/I4210120269 |
| authorships[22].institutions[8].country_code | JP |
| authorships[22].institutions[8].display_name | Taiho Pharmaceutical (Japan) |
| authorships[22].institutions[9].id | https://openalex.org/I2948539688 |
| authorships[22].institutions[9].ror | https://ror.org/02g5p4n58 |
| authorships[22].institutions[9].type | company |
| authorships[22].institutions[9].lineage | https://openalex.org/I2948539688 |
| authorships[22].institutions[9].country_code | US |
| authorships[22].institutions[9].display_name | AbbVie (United States) |
| authorships[22].institutions[10].id | https://openalex.org/I1320553840 |
| authorships[22].institutions[10].ror | https://ror.org/03g03ge92 |
| authorships[22].institutions[10].type | company |
| authorships[22].institutions[10].lineage | https://openalex.org/I1320553840 |
| authorships[22].institutions[10].country_code | US |
| authorships[22].institutions[10].display_name | Amgen (United States) |
| authorships[22].institutions[11].id | https://openalex.org/I4210119928 |
| authorships[22].institutions[11].ror | https://ror.org/02c7apg81 |
| authorships[22].institutions[11].type | company |
| authorships[22].institutions[11].lineage | https://openalex.org/I4210119928 |
| authorships[22].institutions[11].country_code | US |
| authorships[22].institutions[11].display_name | Apexigen (United States) |
| authorships[22].institutions[12].id | https://openalex.org/I4210101899 |
| authorships[22].institutions[12].ror | https://ror.org/018axtd57 |
| authorships[22].institutions[12].type | company |
| authorships[22].institutions[12].lineage | https://openalex.org/I4210101899 |
| authorships[22].institutions[12].country_code | US |
| authorships[22].institutions[12].display_name | Array BioPharma (United States) |
| authorships[22].institutions[13].id | https://openalex.org/I2948663404 |
| authorships[22].institutions[13].ror | https://ror.org/0385es521 |
| authorships[22].institutions[13].type | company |
| authorships[22].institutions[13].lineage | https://openalex.org/I2948663404 |
| authorships[22].institutions[13].country_code | US |
| authorships[22].institutions[13].display_name | Boston Scientific (United States) |
| authorships[22].institutions[14].id | https://openalex.org/I4210108457 |
| authorships[22].institutions[14].ror | https://ror.org/01sfsq511 |
| authorships[22].institutions[14].type | company |
| authorships[22].institutions[14].lineage | https://openalex.org/I4210108457 |
| authorships[22].institutions[14].country_code | US |
| authorships[22].institutions[14].display_name | Infinity Pharmaceuticals (United States) |
| authorships[22].institutions[15].id | https://openalex.org/I4210103611 |
| authorships[22].institutions[15].ror | https://ror.org/01by01460 |
| authorships[22].institutions[15].type | company |
| authorships[22].institutions[15].lineage | https://openalex.org/I4210103611 |
| authorships[22].institutions[15].country_code | US |
| authorships[22].institutions[15].display_name | Mirati Therapeutics (United States) |
| authorships[22].institutions[16].id | https://openalex.org/I4210124059 |
| authorships[22].institutions[16].ror | https://ror.org/02z43nn16 |
| authorships[22].institutions[16].type | company |
| authorships[22].institutions[16].lineage | https://openalex.org/I4210124059 |
| authorships[22].institutions[16].country_code | US |
| authorships[22].institutions[16].display_name | Taiho Oncology (United States) |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Lawrence Jennings |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Array BioPharma Inc.,, Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and, Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals,, GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc.,, Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd.,, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company,, TheraBionic., research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[23].author.id | https://openalex.org/A5019481117 |
| authorships[23].author.orcid | https://orcid.org/0000-0002-1984-2430 |
| authorships[23].author.display_name | Robin Kate Kelley |
| authorships[23].countries | US |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I4210167126 |
| authorships[23].affiliations[0].raw_affiliation_string | UCSF Helen Diller Family Comprehensive Cancer Center; |
| authorships[23].institutions[0].id | https://openalex.org/I4210167126 |
| authorships[23].institutions[0].ror | https://ror.org/05yndxy10 |
| authorships[23].institutions[0].type | facility |
| authorships[23].institutions[0].lineage | https://openalex.org/I180670191, https://openalex.org/I4210110664, https://openalex.org/I4210167126 |
| authorships[23].institutions[0].country_code | US |
| authorships[23].institutions[0].display_name | UCSF Helen Diller Family Comprehensive Cancer Center |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | R. Kate Kelley |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | UCSF Helen Diller Family Comprehensive Cancer Center; |
| authorships[24].author.id | https://openalex.org/A5090353999 |
| authorships[24].author.orcid | https://orcid.org/0000-0002-7820-8229 |
| authorships[24].author.display_name | Robin D. Kim |
| authorships[24].countries | US |
| authorships[24].affiliations[0].institution_ids | https://openalex.org/I223532165, https://openalex.org/I2801159745 |
| authorships[24].affiliations[0].raw_affiliation_string | Huntsman Cancer Institute at the University of Utah; |
| authorships[24].institutions[0].id | https://openalex.org/I2801159745 |
| authorships[24].institutions[0].ror | https://ror.org/03v7tx966 |
| authorships[24].institutions[0].type | healthcare |
| authorships[24].institutions[0].lineage | https://openalex.org/I2801159745, https://openalex.org/I4210148268 |
| authorships[24].institutions[0].country_code | US |
| authorships[24].institutions[0].display_name | Huntsman Cancer Institute |
| authorships[24].institutions[1].id | https://openalex.org/I223532165 |
| authorships[24].institutions[1].ror | https://ror.org/03r0ha626 |
| authorships[24].institutions[1].type | education |
| authorships[24].institutions[1].lineage | https://openalex.org/I223532165 |
| authorships[24].institutions[1].country_code | US |
| authorships[24].institutions[1].display_name | University of Utah |
| authorships[24].author_position | middle |
| authorships[24].raw_author_name | Robin Kim |
| authorships[24].is_corresponding | False |
| authorships[24].raw_affiliation_strings | Huntsman Cancer Institute at the University of Utah; |
| authorships[25].author.id | https://openalex.org/A5000292345 |
| authorships[25].author.orcid | https://orcid.org/0000-0003-4525-5827 |
| authorships[25].author.display_name | Matthew H. Levine |
| authorships[25].countries | US |
| authorships[25].affiliations[0].institution_ids | https://openalex.org/I79576946 |
| authorships[25].affiliations[0].raw_affiliation_string | Abramson Cancer Center at the University of Pennsylvania; |
| authorships[25].institutions[0].id | https://openalex.org/I79576946 |
| authorships[25].institutions[0].ror | https://ror.org/00b30xv10 |
| authorships[25].institutions[0].type | education |
| authorships[25].institutions[0].lineage | https://openalex.org/I79576946 |
| authorships[25].institutions[0].country_code | US |
| authorships[25].institutions[0].display_name | University of Pennsylvania |
| authorships[25].author_position | middle |
| authorships[25].raw_author_name | Matthew Levine |
| authorships[25].is_corresponding | False |
| authorships[25].raw_affiliation_strings | Abramson Cancer Center at the University of Pennsylvania; |
| authorships[26].author.id | https://openalex.org/A5019376688 |
| authorships[26].author.orcid | https://orcid.org/0000-0002-9085-9075 |
| authorships[26].author.display_name | Manisha Palta |
| authorships[26].countries | IN, US, ZA |
| authorships[26].affiliations[0].institution_ids | https://openalex.org/I1326427960, https://openalex.org/I2801345345, https://openalex.org/I4210089486, https://openalex.org/I4390039326 |
| authorships[26].affiliations[0].raw_affiliation_string | Duke Cancer Institute; 26 Fred Hutchinson Cancer Center; |
| authorships[26].institutions[0].id | https://openalex.org/I4390039326 |
| authorships[26].institutions[0].ror | https://ror.org/04vt65461 |
| authorships[26].institutions[0].type | healthcare |
| authorships[26].institutions[0].lineage | https://openalex.org/I4210126298, https://openalex.org/I4210144876, https://openalex.org/I4390039326 |
| authorships[26].institutions[0].country_code | |
| authorships[26].institutions[0].display_name | Duke Cancer Institute |
| authorships[26].institutions[1].id | https://openalex.org/I2801345345 |
| authorships[26].institutions[1].ror | https://ror.org/01tc10z29 |
| authorships[26].institutions[1].type | healthcare |
| authorships[26].institutions[1].lineage | https://openalex.org/I2801345345 |
| authorships[26].institutions[1].country_code | IN |
| authorships[26].institutions[1].display_name | Cancer Institute (WIA) |
| authorships[26].institutions[2].id | https://openalex.org/I4210089486 |
| authorships[26].institutions[2].ror | https://ror.org/007ps6h72 |
| authorships[26].institutions[2].type | nonprofit |
| authorships[26].institutions[2].lineage | https://openalex.org/I4210089486 |
| authorships[26].institutions[2].country_code | US |
| authorships[26].institutions[2].display_name | Fred Hutch Cancer Center |
| authorships[26].institutions[3].id | https://openalex.org/I1326427960 |
| authorships[26].institutions[3].ror | https://ror.org/00wdsp051 |
| authorships[26].institutions[3].type | nonprofit |
| authorships[26].institutions[3].lineage | https://openalex.org/I1326427960, https://openalex.org/I4210089486 |
| authorships[26].institutions[3].country_code | ZA |
| authorships[26].institutions[3].display_name | Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa |
| authorships[26].author_position | middle |
| authorships[26].raw_author_name | Manisha Palta |
| authorships[26].is_corresponding | False |
| authorships[26].raw_affiliation_strings | Duke Cancer Institute; 26 Fred Hutchinson Cancer Center; |
| authorships[27].author.id | https://openalex.org/A5053526360 |
| authorships[27].author.orcid | https://orcid.org/0000-0001-6939-1255 |
| authorships[27].author.display_name | James O. Park |
| authorships[27].countries | BE, CH, CN, DE, GB, IN, JP, US |
| authorships[27].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center of Northwestern University; |
| authorships[27].affiliations[1].institution_ids | https://openalex.org/I157075465 |
| authorships[27].affiliations[1].raw_affiliation_string | ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company, |
| authorships[27].affiliations[2].institution_ids | https://openalex.org/I189718659, https://openalex.org/I4210117523, https://openalex.org/I4210120269, https://openalex.org/I4210124059 |
| authorships[27].affiliations[2].raw_affiliation_string | Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd., |
| authorships[27].affiliations[3].institution_ids | https://openalex.org/I4210101899 |
| authorships[27].affiliations[3].raw_affiliation_string | Array BioPharma Inc., |
| authorships[27].affiliations[4].institution_ids | https://openalex.org/I1283582996, https://openalex.org/I2948663404, https://openalex.org/I4210088994, https://openalex.org/I4210103611 |
| authorships[27].affiliations[4].raw_affiliation_string | Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and |
| authorships[27].affiliations[5].institution_ids | https://openalex.org/I137982388, https://openalex.org/I189718659, https://openalex.org/I4210108457 |
| authorships[27].affiliations[5].raw_affiliation_string | Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals, |
| authorships[27].affiliations[6].institution_ids | https://openalex.org/I1320553840, https://openalex.org/I2948539688, https://openalex.org/I4210119928 |
| authorships[27].affiliations[6].raw_affiliation_string | research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[27].affiliations[7].raw_affiliation_string | TheraBionic. |
| authorships[27].affiliations[8].institution_ids | https://openalex.org/I137982388, https://openalex.org/I4210099842, https://openalex.org/I4210103611 |
| authorships[27].affiliations[8].raw_affiliation_string | GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc., |
| authorships[27].institutions[0].id | https://openalex.org/I137982388 |
| authorships[27].institutions[0].ror | https://ror.org/04yzcpd71 |
| authorships[27].institutions[0].type | company |
| authorships[27].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[27].institutions[0].country_code | BE |
| authorships[27].institutions[0].display_name | Janssen (Belgium) |
| authorships[27].institutions[1].id | https://openalex.org/I1283582996 |
| authorships[27].institutions[1].ror | https://ror.org/02f9zrr09 |
| authorships[27].institutions[1].type | company |
| authorships[27].institutions[1].lineage | https://openalex.org/I1283582996 |
| authorships[27].institutions[1].country_code | CH |
| authorships[27].institutions[1].display_name | Novartis (Switzerland) |
| authorships[27].institutions[2].id | https://openalex.org/I4210088994 |
| authorships[27].institutions[2].ror | https://ror.org/008h8bh21 |
| authorships[27].institutions[2].type | company |
| authorships[27].institutions[2].lineage | https://openalex.org/I142395110, https://openalex.org/I4210088994 |
| authorships[27].institutions[2].country_code | CN |
| authorships[27].institutions[2].display_name | Astellas Pharma (China) |
| authorships[27].institutions[3].id | https://openalex.org/I157075465 |
| authorships[27].institutions[3].ror | https://ror.org/032hfv632 |
| authorships[27].institutions[3].type | company |
| authorships[27].institutions[3].lineage | https://openalex.org/I157075465, https://openalex.org/I4210091812 |
| authorships[27].institutions[3].country_code | DE |
| authorships[27].institutions[3].display_name | Bristol-Myers Squibb (Germany) |
| authorships[27].institutions[4].id | https://openalex.org/I189718659 |
| authorships[27].institutions[4].ror | https://ror.org/04x4v8p40 |
| authorships[27].institutions[4].type | company |
| authorships[27].institutions[4].lineage | https://openalex.org/I180857899, https://openalex.org/I189718659 |
| authorships[27].institutions[4].country_code | GB |
| authorships[27].institutions[4].display_name | Pfizer (United Kingdom) |
| authorships[27].institutions[5].id | https://openalex.org/I4210117523 |
| authorships[27].institutions[5].ror | https://ror.org/01w6gjq94 |
| authorships[27].institutions[5].type | company |
| authorships[27].institutions[5].lineage | https://openalex.org/I2250650973, https://openalex.org/I4210117523 |
| authorships[27].institutions[5].country_code | GB |
| authorships[27].institutions[5].display_name | Samsung (United Kingdom) |
| authorships[27].institutions[6].id | https://openalex.org/I4210099842 |
| authorships[27].institutions[6].ror | https://ror.org/01tvt4d48 |
| authorships[27].institutions[6].type | company |
| authorships[27].institutions[6].lineage | https://openalex.org/I188950975, https://openalex.org/I4210099842 |
| authorships[27].institutions[6].country_code | IN |
| authorships[27].institutions[6].display_name | GlaxoSmithKline (India) |
| authorships[27].institutions[7].id | https://openalex.org/I4210120269 |
| authorships[27].institutions[7].ror | https://ror.org/02v50dx14 |
| authorships[27].institutions[7].type | company |
| authorships[27].institutions[7].lineage | https://openalex.org/I4210120269 |
| authorships[27].institutions[7].country_code | JP |
| authorships[27].institutions[7].display_name | Taiho Pharmaceutical (Japan) |
| authorships[27].institutions[8].id | https://openalex.org/I2948539688 |
| authorships[27].institutions[8].ror | https://ror.org/02g5p4n58 |
| authorships[27].institutions[8].type | company |
| authorships[27].institutions[8].lineage | https://openalex.org/I2948539688 |
| authorships[27].institutions[8].country_code | US |
| authorships[27].institutions[8].display_name | AbbVie (United States) |
| authorships[27].institutions[9].id | https://openalex.org/I1320553840 |
| authorships[27].institutions[9].ror | https://ror.org/03g03ge92 |
| authorships[27].institutions[9].type | company |
| authorships[27].institutions[9].lineage | https://openalex.org/I1320553840 |
| authorships[27].institutions[9].country_code | US |
| authorships[27].institutions[9].display_name | Amgen (United States) |
| authorships[27].institutions[10].id | https://openalex.org/I4210119928 |
| authorships[27].institutions[10].ror | https://ror.org/02c7apg81 |
| authorships[27].institutions[10].type | company |
| authorships[27].institutions[10].lineage | https://openalex.org/I4210119928 |
| authorships[27].institutions[10].country_code | US |
| authorships[27].institutions[10].display_name | Apexigen (United States) |
| authorships[27].institutions[11].id | https://openalex.org/I4210101899 |
| authorships[27].institutions[11].ror | https://ror.org/018axtd57 |
| authorships[27].institutions[11].type | company |
| authorships[27].institutions[11].lineage | https://openalex.org/I4210101899 |
| authorships[27].institutions[11].country_code | US |
| authorships[27].institutions[11].display_name | Array BioPharma (United States) |
| authorships[27].institutions[12].id | https://openalex.org/I2948663404 |
| authorships[27].institutions[12].ror | https://ror.org/0385es521 |
| authorships[27].institutions[12].type | company |
| authorships[27].institutions[12].lineage | https://openalex.org/I2948663404 |
| authorships[27].institutions[12].country_code | US |
| authorships[27].institutions[12].display_name | Boston Scientific (United States) |
| authorships[27].institutions[13].id | https://openalex.org/I4210108457 |
| authorships[27].institutions[13].ror | https://ror.org/01sfsq511 |
| authorships[27].institutions[13].type | company |
| authorships[27].institutions[13].lineage | https://openalex.org/I4210108457 |
| authorships[27].institutions[13].country_code | US |
| authorships[27].institutions[13].display_name | Infinity Pharmaceuticals (United States) |
| authorships[27].institutions[14].id | https://openalex.org/I4210103611 |
| authorships[27].institutions[14].ror | https://ror.org/01by01460 |
| authorships[27].institutions[14].type | company |
| authorships[27].institutions[14].lineage | https://openalex.org/I4210103611 |
| authorships[27].institutions[14].country_code | US |
| authorships[27].institutions[14].display_name | Mirati Therapeutics (United States) |
| authorships[27].institutions[15].id | https://openalex.org/I4210124059 |
| authorships[27].institutions[15].ror | https://ror.org/02z43nn16 |
| authorships[27].institutions[15].type | company |
| authorships[27].institutions[15].lineage | https://openalex.org/I4210124059 |
| authorships[27].institutions[15].country_code | US |
| authorships[27].institutions[15].display_name | Taiho Oncology (United States) |
| authorships[27].author_position | middle |
| authorships[27].raw_author_name | James O. Park |
| authorships[27].is_corresponding | False |
| authorships[27].raw_affiliation_strings | Array BioPharma Inc.,, Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and, Comprehensive Cancer Center of Northwestern University;, Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals,, GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc.,, Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd.,, ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company,, TheraBionic., research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[28].author.id | https://openalex.org/A5058617146 |
| authorships[28].author.orcid | https://orcid.org/0000-0003-0499-1676 |
| authorships[28].author.display_name | Steven S. Raman |
| authorships[28].affiliations[0].institution_ids | https://openalex.org/I4390039293 |
| authorships[28].affiliations[0].raw_affiliation_string | UCLA Jonsson Comprehensive Cancer Center; |
| authorships[28].institutions[0].id | https://openalex.org/I4390039293 |
| authorships[28].institutions[0].ror | https://ror.org/0599cs764 |
| authorships[28].institutions[0].type | healthcare |
| authorships[28].institutions[0].lineage | https://openalex.org/I2799798094, https://openalex.org/I4390039293 |
| authorships[28].institutions[0].country_code | |
| authorships[28].institutions[0].display_name | UCLA Jonsson Comprehensive Cancer Center |
| authorships[28].author_position | middle |
| authorships[28].raw_author_name | Steven Raman |
| authorships[28].is_corresponding | False |
| authorships[28].raw_affiliation_strings | UCLA Jonsson Comprehensive Cancer Center; |
| authorships[29].author.id | https://openalex.org/A5001339565 |
| authorships[29].author.orcid | https://orcid.org/0000-0001-9306-2574 |
| authorships[29].author.display_name | Sanjay S. Reddy |
| authorships[29].countries | BE, CH, CN, DE, GB, IN, JP, US |
| authorships[29].affiliations[0].institution_ids | https://openalex.org/I137982388, https://openalex.org/I4210099842, https://openalex.org/I4210103611 |
| authorships[29].affiliations[0].raw_affiliation_string | GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc., |
| authorships[29].affiliations[1].raw_affiliation_string | TheraBionic. |
| authorships[29].affiliations[2].institution_ids | https://openalex.org/I137982388, https://openalex.org/I189718659, https://openalex.org/I4210108457 |
| authorships[29].affiliations[2].raw_affiliation_string | Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals, |
| authorships[29].affiliations[3].institution_ids | https://openalex.org/I4210101899 |
| authorships[29].affiliations[3].raw_affiliation_string | Array BioPharma Inc., |
| authorships[29].affiliations[4].institution_ids | https://openalex.org/I1320553840, https://openalex.org/I2948539688, https://openalex.org/I4210119928 |
| authorships[29].affiliations[4].raw_affiliation_string | research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[29].affiliations[5].institution_ids | https://openalex.org/I1283582996, https://openalex.org/I2948663404, https://openalex.org/I4210088994, https://openalex.org/I4210103611 |
| authorships[29].affiliations[5].raw_affiliation_string | Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and |
| authorships[29].affiliations[6].raw_affiliation_string | Comprehensive Cancer Center of Northwestern University; |
| authorships[29].affiliations[7].institution_ids | https://openalex.org/I157075465 |
| authorships[29].affiliations[7].raw_affiliation_string | ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company, |
| authorships[29].affiliations[8].institution_ids | https://openalex.org/I189718659, https://openalex.org/I4210117523, https://openalex.org/I4210120269, https://openalex.org/I4210124059 |
| authorships[29].affiliations[8].raw_affiliation_string | Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd., |
| authorships[29].institutions[0].id | https://openalex.org/I137982388 |
| authorships[29].institutions[0].ror | https://ror.org/04yzcpd71 |
| authorships[29].institutions[0].type | company |
| authorships[29].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[29].institutions[0].country_code | BE |
| authorships[29].institutions[0].display_name | Janssen (Belgium) |
| authorships[29].institutions[1].id | https://openalex.org/I1283582996 |
| authorships[29].institutions[1].ror | https://ror.org/02f9zrr09 |
| authorships[29].institutions[1].type | company |
| authorships[29].institutions[1].lineage | https://openalex.org/I1283582996 |
| authorships[29].institutions[1].country_code | CH |
| authorships[29].institutions[1].display_name | Novartis (Switzerland) |
| authorships[29].institutions[2].id | https://openalex.org/I4210088994 |
| authorships[29].institutions[2].ror | https://ror.org/008h8bh21 |
| authorships[29].institutions[2].type | company |
| authorships[29].institutions[2].lineage | https://openalex.org/I142395110, https://openalex.org/I4210088994 |
| authorships[29].institutions[2].country_code | CN |
| authorships[29].institutions[2].display_name | Astellas Pharma (China) |
| authorships[29].institutions[3].id | https://openalex.org/I157075465 |
| authorships[29].institutions[3].ror | https://ror.org/032hfv632 |
| authorships[29].institutions[3].type | company |
| authorships[29].institutions[3].lineage | https://openalex.org/I157075465, https://openalex.org/I4210091812 |
| authorships[29].institutions[3].country_code | DE |
| authorships[29].institutions[3].display_name | Bristol-Myers Squibb (Germany) |
| authorships[29].institutions[4].id | https://openalex.org/I189718659 |
| authorships[29].institutions[4].ror | https://ror.org/04x4v8p40 |
| authorships[29].institutions[4].type | company |
| authorships[29].institutions[4].lineage | https://openalex.org/I180857899, https://openalex.org/I189718659 |
| authorships[29].institutions[4].country_code | GB |
| authorships[29].institutions[4].display_name | Pfizer (United Kingdom) |
| authorships[29].institutions[5].id | https://openalex.org/I4210117523 |
| authorships[29].institutions[5].ror | https://ror.org/01w6gjq94 |
| authorships[29].institutions[5].type | company |
| authorships[29].institutions[5].lineage | https://openalex.org/I2250650973, https://openalex.org/I4210117523 |
| authorships[29].institutions[5].country_code | GB |
| authorships[29].institutions[5].display_name | Samsung (United Kingdom) |
| authorships[29].institutions[6].id | https://openalex.org/I4210099842 |
| authorships[29].institutions[6].ror | https://ror.org/01tvt4d48 |
| authorships[29].institutions[6].type | company |
| authorships[29].institutions[6].lineage | https://openalex.org/I188950975, https://openalex.org/I4210099842 |
| authorships[29].institutions[6].country_code | IN |
| authorships[29].institutions[6].display_name | GlaxoSmithKline (India) |
| authorships[29].institutions[7].id | https://openalex.org/I4210120269 |
| authorships[29].institutions[7].ror | https://ror.org/02v50dx14 |
| authorships[29].institutions[7].type | company |
| authorships[29].institutions[7].lineage | https://openalex.org/I4210120269 |
| authorships[29].institutions[7].country_code | JP |
| authorships[29].institutions[7].display_name | Taiho Pharmaceutical (Japan) |
| authorships[29].institutions[8].id | https://openalex.org/I2948539688 |
| authorships[29].institutions[8].ror | https://ror.org/02g5p4n58 |
| authorships[29].institutions[8].type | company |
| authorships[29].institutions[8].lineage | https://openalex.org/I2948539688 |
| authorships[29].institutions[8].country_code | US |
| authorships[29].institutions[8].display_name | AbbVie (United States) |
| authorships[29].institutions[9].id | https://openalex.org/I1320553840 |
| authorships[29].institutions[9].ror | https://ror.org/03g03ge92 |
| authorships[29].institutions[9].type | company |
| authorships[29].institutions[9].lineage | https://openalex.org/I1320553840 |
| authorships[29].institutions[9].country_code | US |
| authorships[29].institutions[9].display_name | Amgen (United States) |
| authorships[29].institutions[10].id | https://openalex.org/I4210119928 |
| authorships[29].institutions[10].ror | https://ror.org/02c7apg81 |
| authorships[29].institutions[10].type | company |
| authorships[29].institutions[10].lineage | https://openalex.org/I4210119928 |
| authorships[29].institutions[10].country_code | US |
| authorships[29].institutions[10].display_name | Apexigen (United States) |
| authorships[29].institutions[11].id | https://openalex.org/I4210101899 |
| authorships[29].institutions[11].ror | https://ror.org/018axtd57 |
| authorships[29].institutions[11].type | company |
| authorships[29].institutions[11].lineage | https://openalex.org/I4210101899 |
| authorships[29].institutions[11].country_code | US |
| authorships[29].institutions[11].display_name | Array BioPharma (United States) |
| authorships[29].institutions[12].id | https://openalex.org/I2948663404 |
| authorships[29].institutions[12].ror | https://ror.org/0385es521 |
| authorships[29].institutions[12].type | company |
| authorships[29].institutions[12].lineage | https://openalex.org/I2948663404 |
| authorships[29].institutions[12].country_code | US |
| authorships[29].institutions[12].display_name | Boston Scientific (United States) |
| authorships[29].institutions[13].id | https://openalex.org/I4210108457 |
| authorships[29].institutions[13].ror | https://ror.org/01sfsq511 |
| authorships[29].institutions[13].type | company |
| authorships[29].institutions[13].lineage | https://openalex.org/I4210108457 |
| authorships[29].institutions[13].country_code | US |
| authorships[29].institutions[13].display_name | Infinity Pharmaceuticals (United States) |
| authorships[29].institutions[14].id | https://openalex.org/I4210103611 |
| authorships[29].institutions[14].ror | https://ror.org/01by01460 |
| authorships[29].institutions[14].type | company |
| authorships[29].institutions[14].lineage | https://openalex.org/I4210103611 |
| authorships[29].institutions[14].country_code | US |
| authorships[29].institutions[14].display_name | Mirati Therapeutics (United States) |
| authorships[29].institutions[15].id | https://openalex.org/I4210124059 |
| authorships[29].institutions[15].ror | https://ror.org/02z43nn16 |
| authorships[29].institutions[15].type | company |
| authorships[29].institutions[15].lineage | https://openalex.org/I4210124059 |
| authorships[29].institutions[15].country_code | US |
| authorships[29].institutions[15].display_name | Taiho Oncology (United States) |
| authorships[29].author_position | middle |
| authorships[29].raw_author_name | Sanjay Reddy |
| authorships[29].is_corresponding | False |
| authorships[29].raw_affiliation_strings | Array BioPharma Inc.,, Astellas Pharma US, Inc., Boston Scientific Corporation, HUTCHMED, Mirati Therapeutics, Inc., Natera Inc., Novartis Pharmaceuticals Corporation, SeaGen, Tempus, and, Comprehensive Cancer Center of Northwestern University;, Elevar Therapeutics, Infinity Pharmaceuticals, Inc., ITM Solucin, MedImmune Inc., Janssen Pharmaceutica Products, LP, Merck Sharpe & Dohme Ltd, Pfizer Inc., Rafael Pharmaceuticals,, GlaxoSmithKline, GRAIL, HalioDx, Janssen Pharmaceutica Products, LP, Mirati Therapeutics, Inc., Nuvation Bio, Inc.,, Pfizer Inc., Samsung Bioepis, SeaGen, Taiho Pharmaceuticals Co., Ltd.,, ST Pharm Co. Ltd, SynCore Biotechnology, and TYME Technologies, Inc.; receiving consulting fees from Aveo Oncology, Boston Scientific Corporation, Bristol-Myers Squibb Company,, TheraBionic., research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, |
| authorships[30].author.id | https://openalex.org/A5032788721 |
| authorships[30].author.orcid | https://orcid.org/0000-0001-6664-996X |
| authorships[30].author.display_name | Sean M. Ronnekleiv‐Kelly |
| authorships[30].countries | US |
| authorships[30].affiliations[0].institution_ids | https://openalex.org/I4210103341 |
| authorships[30].affiliations[0].raw_affiliation_string | University of Wisconsin Carbone Cancer Center; |
| authorships[30].institutions[0].id | https://openalex.org/I4210103341 |
| authorships[30].institutions[0].ror | https://ror.org/01e4byj08 |
| authorships[30].institutions[0].type | healthcare |
| authorships[30].institutions[0].lineage | https://openalex.org/I2799905417, https://openalex.org/I4210103341, https://openalex.org/I4210132596 |
| authorships[30].institutions[0].country_code | US |
| authorships[30].institutions[0].display_name | University of Wisconsin Carbone Cancer Center |
| authorships[30].author_position | middle |
| authorships[30].raw_author_name | Sean Ronnekleiv-Kelly |
| authorships[30].is_corresponding | False |
| authorships[30].raw_affiliation_strings | University of Wisconsin Carbone Cancer Center; |
| authorships[31].author.id | https://openalex.org/A5076767039 |
| authorships[31].author.orcid | https://orcid.org/0000-0003-1892-1548 |
| authorships[31].author.display_name | Vaibhav Sahai |
| authorships[31].countries | US |
| authorships[31].affiliations[0].institution_ids | https://openalex.org/I27837315 |
| authorships[31].affiliations[0].raw_affiliation_string | University of Michigan Rogel Cancer Center; |
| authorships[31].institutions[0].id | https://openalex.org/I27837315 |
| authorships[31].institutions[0].ror | https://ror.org/00jmfr291 |
| authorships[31].institutions[0].type | education |
| authorships[31].institutions[0].lineage | https://openalex.org/I27837315 |
| authorships[31].institutions[0].country_code | US |
| authorships[31].institutions[0].display_name | University of Michigan |
| authorships[31].author_position | middle |
| authorships[31].raw_author_name | Vaibhav Sahai |
| authorships[31].is_corresponding | False |
| authorships[31].raw_affiliation_strings | University of Michigan Rogel Cancer Center; |
| authorships[32].author.id | https://openalex.org/A5019126958 |
| authorships[32].author.orcid | https://orcid.org/0000-0002-4743-4696 |
| authorships[32].author.display_name | Gagandeep Singh |
| authorships[32].countries | US |
| authorships[32].affiliations[0].institution_ids | https://openalex.org/I1301076528 |
| authorships[32].affiliations[0].raw_affiliation_string | City of Hope National Medical Center; |
| authorships[32].institutions[0].id | https://openalex.org/I1301076528 |
| authorships[32].institutions[0].ror | https://ror.org/00w6g5w60 |
| authorships[32].institutions[0].type | healthcare |
| authorships[32].institutions[0].lineage | https://openalex.org/I1301076528 |
| authorships[32].institutions[0].country_code | US |
| authorships[32].institutions[0].display_name | City Of Hope National Medical Center |
| authorships[32].author_position | middle |
| authorships[32].raw_author_name | Gagandeep Singh |
| authorships[32].is_corresponding | False |
| authorships[32].raw_affiliation_strings | City of Hope National Medical Center; |
| authorships[33].author.id | https://openalex.org/A5012787104 |
| authorships[33].author.orcid | https://orcid.org/0000-0001-8970-9144 |
| authorships[33].author.display_name | Stacey Stein |
| authorships[33].countries | US |
| authorships[33].affiliations[0].institution_ids | https://openalex.org/I2802730090, https://openalex.org/I4210165192 |
| authorships[33].affiliations[0].raw_affiliation_string | Yale Cancer Center/Smilow Cancer Hospital; |
| authorships[33].institutions[0].id | https://openalex.org/I4210165192 |
| authorships[33].institutions[0].ror | https://ror.org/05q3szf80 |
| authorships[33].institutions[0].type | healthcare |
| authorships[33].institutions[0].lineage | https://openalex.org/I4210117499, https://openalex.org/I4210165192 |
| authorships[33].institutions[0].country_code | US |
| authorships[33].institutions[0].display_name | Smilow Cancer Hospital |
| authorships[33].institutions[1].id | https://openalex.org/I2802730090 |
| authorships[33].institutions[1].ror | https://ror.org/03j7sze86 |
| authorships[33].institutions[1].type | facility |
| authorships[33].institutions[1].lineage | https://openalex.org/I2802730090, https://openalex.org/I4210117499, https://openalex.org/I4210165192 |
| authorships[33].institutions[1].country_code | US |
| authorships[33].institutions[1].display_name | Yale Cancer Center |
| authorships[33].author_position | middle |
| authorships[33].raw_author_name | Stacey Stein |
| authorships[33].is_corresponding | False |
| authorships[33].raw_affiliation_strings | Yale Cancer Center/Smilow Cancer Hospital; |
| authorships[34].author.id | https://openalex.org/A5030878684 |
| authorships[34].author.orcid | https://orcid.org/0000-0002-4159-5376 |
| authorships[34].author.display_name | Anita Turk |
| authorships[34].countries | US |
| authorships[34].affiliations[0].institution_ids | https://openalex.org/I4390039234, https://openalex.org/I592451 |
| authorships[34].affiliations[0].raw_affiliation_string | Indiana University Melvin and Bren Simon Comprehensive Cancer Center; |
| authorships[34].institutions[0].id | https://openalex.org/I4390039234 |
| authorships[34].institutions[0].ror | https://ror.org/00g1d7b60 |
| authorships[34].institutions[0].type | healthcare |
| authorships[34].institutions[0].lineage | https://openalex.org/I4390039234, https://openalex.org/I592451 |
| authorships[34].institutions[0].country_code | |
| authorships[34].institutions[0].display_name | Indiana University Melvin and Bren Simon Comprehensive Cancer Center |
| authorships[34].institutions[1].id | https://openalex.org/I592451 |
| authorships[34].institutions[1].ror | https://ror.org/01kg8sb98 |
| authorships[34].institutions[1].type | education |
| authorships[34].institutions[1].lineage | https://openalex.org/I592451 |
| authorships[34].institutions[1].country_code | US |
| authorships[34].institutions[1].display_name | Indiana University |
| authorships[34].author_position | middle |
| authorships[34].raw_author_name | Anita Turk |
| authorships[34].is_corresponding | False |
| authorships[34].raw_affiliation_strings | Indiana University Melvin and Bren Simon Comprehensive Cancer Center; |
| authorships[35].author.id | https://openalex.org/A5085656655 |
| authorships[35].author.orcid | https://orcid.org/0000-0003-4921-5427 |
| authorships[35].author.display_name | Jean‐Nicolas Vauthey |
| authorships[35].countries | US |
| authorships[35].affiliations[0].institution_ids | https://openalex.org/I1343551460 |
| authorships[35].affiliations[0].raw_affiliation_string | The University of Texas MD Anderson Cancer Center; |
| authorships[35].institutions[0].id | https://openalex.org/I1343551460 |
| authorships[35].institutions[0].ror | https://ror.org/04twxam07 |
| authorships[35].institutions[0].type | healthcare |
| authorships[35].institutions[0].lineage | https://openalex.org/I1343551460 |
| authorships[35].institutions[0].country_code | US |
| authorships[35].institutions[0].display_name | The University of Texas MD Anderson Cancer Center |
| authorships[35].author_position | middle |
| authorships[35].raw_author_name | Jean-Nicolas Vauthey |
| authorships[35].is_corresponding | False |
| authorships[35].raw_affiliation_strings | The University of Texas MD Anderson Cancer Center; |
| authorships[36].author.id | https://openalex.org/A5037875642 |
| authorships[36].author.orcid | https://orcid.org/0000-0001-9749-6548 |
| authorships[36].author.display_name | Alan P. Venook |
| authorships[36].countries | US |
| authorships[36].affiliations[0].institution_ids | https://openalex.org/I4210167126 |
| authorships[36].affiliations[0].raw_affiliation_string | UCSF Helen Diller Family Comprehensive Cancer Center; |
| authorships[36].institutions[0].id | https://openalex.org/I4210167126 |
| authorships[36].institutions[0].ror | https://ror.org/05yndxy10 |
| authorships[36].institutions[0].type | facility |
| authorships[36].institutions[0].lineage | https://openalex.org/I180670191, https://openalex.org/I4210110664, https://openalex.org/I4210167126 |
| authorships[36].institutions[0].country_code | US |
| authorships[36].institutions[0].display_name | UCSF Helen Diller Family Comprehensive Cancer Center |
| authorships[36].author_position | middle |
| authorships[36].raw_author_name | Alan P. Venook |
| authorships[36].is_corresponding | False |
| authorships[36].raw_affiliation_strings | UCSF Helen Diller Family Comprehensive Cancer Center; |
| authorships[37].author.id | https://openalex.org/A5085283718 |
| authorships[37].author.orcid | https://orcid.org/0000-0002-5887-5315 |
| authorships[37].author.display_name | Adam C. Yopp |
| authorships[37].countries | US |
| authorships[37].affiliations[0].institution_ids | https://openalex.org/I4390039370, https://openalex.org/I867280407 |
| authorships[37].affiliations[0].raw_affiliation_string | UT Southwestern Simmons Comprehensive Cancer Center; and |
| authorships[37].institutions[0].id | https://openalex.org/I4390039370 |
| authorships[37].institutions[0].ror | https://ror.org/03cbz4r60 |
| authorships[37].institutions[0].type | healthcare |
| authorships[37].institutions[0].lineage | https://openalex.org/I4390039370, https://openalex.org/I867280407 |
| authorships[37].institutions[0].country_code | |
| authorships[37].institutions[0].display_name | Harold C. Simmons Comprehensive Cancer Center |
| authorships[37].institutions[1].id | https://openalex.org/I867280407 |
| authorships[37].institutions[1].ror | https://ror.org/05byvp690 |
| authorships[37].institutions[1].type | education |
| authorships[37].institutions[1].lineage | https://openalex.org/I867280407 |
| authorships[37].institutions[1].country_code | US |
| authorships[37].institutions[1].display_name | The University of Texas Southwestern Medical Center |
| authorships[37].author_position | middle |
| authorships[37].raw_author_name | Adam Yopp |
| authorships[37].is_corresponding | False |
| authorships[37].raw_affiliation_strings | UT Southwestern Simmons Comprehensive Cancer Center; and |
| authorships[38].author.id | https://openalex.org/A5014986824 |
| authorships[38].author.orcid | |
| authorships[38].author.display_name | Nicole R. McMillian |
| authorships[38].affiliations[0].institution_ids | https://openalex.org/I4391768124 |
| authorships[38].affiliations[0].raw_affiliation_string | National Comprehensive Cancer Network. |
| authorships[38].institutions[0].id | https://openalex.org/I4391768124 |
| authorships[38].institutions[0].ror | https://ror.org/0465x5x63 |
| authorships[38].institutions[0].type | government |
| authorships[38].institutions[0].lineage | https://openalex.org/I4391768124 |
| authorships[38].institutions[0].country_code | |
| authorships[38].institutions[0].display_name | National Comprehensive Cancer Network |
| authorships[38].author_position | middle |
| authorships[38].raw_author_name | Nicole McMillian |
| authorships[38].is_corresponding | False |
| authorships[38].raw_affiliation_strings | National Comprehensive Cancer Network. |
| authorships[39].author.id | https://openalex.org/A5065392753 |
| authorships[39].author.orcid | |
| authorships[39].author.display_name | Ryan Schonfeld |
| authorships[39].affiliations[0].institution_ids | https://openalex.org/I4391768124 |
| authorships[39].affiliations[0].raw_affiliation_string | National Comprehensive Cancer Network. |
| authorships[39].institutions[0].id | https://openalex.org/I4391768124 |
| authorships[39].institutions[0].ror | https://ror.org/0465x5x63 |
| authorships[39].institutions[0].type | government |
| authorships[39].institutions[0].lineage | https://openalex.org/I4391768124 |
| authorships[39].institutions[0].country_code | |
| authorships[39].institutions[0].display_name | National Comprehensive Cancer Network |
| authorships[39].author_position | middle |
| authorships[39].raw_author_name | Ryan Schonfeld |
| authorships[39].is_corresponding | False |
| authorships[39].raw_affiliation_strings | National Comprehensive Cancer Network. |
| authorships[40].author.id | https://openalex.org/A5054568851 |
| authorships[40].author.orcid | |
| authorships[40].author.display_name | Cindy Hochstetler |
| authorships[40].affiliations[0].institution_ids | https://openalex.org/I4391768124 |
| authorships[40].affiliations[0].raw_affiliation_string | National Comprehensive Cancer Network. |
| authorships[40].institutions[0].id | https://openalex.org/I4391768124 |
| authorships[40].institutions[0].ror | https://ror.org/0465x5x63 |
| authorships[40].institutions[0].type | government |
| authorships[40].institutions[0].lineage | https://openalex.org/I4391768124 |
| authorships[40].institutions[0].country_code | |
| authorships[40].institutions[0].display_name | National Comprehensive Cancer Network |
| authorships[40].author_position | last |
| authorships[40].raw_author_name | Cindy Hochstetler |
| authorships[40].is_corresponding | False |
| authorships[40].raw_affiliation_strings | National Comprehensive Cancer Network. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://jnccn.org/downloadpdf/journals/jnccn/21/7/article-p694.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023 |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11364 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Cholangiocarcinoma and Gallbladder Cancer Studies |
| related_works | https://openalex.org/W2999558212, https://openalex.org/W2433476178, https://openalex.org/W2589790871, https://openalex.org/W4308507060, https://openalex.org/W2388665344, https://openalex.org/W4313319224, https://openalex.org/W2429757858, https://openalex.org/W4386362288, https://openalex.org/W4320491686, https://openalex.org/W2477621153 |
| cited_by_count | 164 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 80 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 77 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 7 |
| locations_count | 2 |
| best_oa_location.id | doi:10.6004/jnccn.2023.0035 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S935620192 |
| best_oa_location.source.issn | 1540-1405, 1540-1413 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1540-1405 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of the National Comprehensive Cancer Network |
| best_oa_location.source.host_organization | https://openalex.org/P4324004213 |
| best_oa_location.source.host_organization_name | National Comprehensive Cancer |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4324004213 |
| best_oa_location.source.host_organization_lineage_names | National Comprehensive Cancer |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://jnccn.org/downloadpdf/journals/jnccn/21/7/article-p694.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of the National Comprehensive Cancer Network |
| best_oa_location.landing_page_url | https://doi.org/10.6004/jnccn.2023.0035 |
| primary_location.id | doi:10.6004/jnccn.2023.0035 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S935620192 |
| primary_location.source.issn | 1540-1405, 1540-1413 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1540-1405 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of the National Comprehensive Cancer Network |
| primary_location.source.host_organization | https://openalex.org/P4324004213 |
| primary_location.source.host_organization_name | National Comprehensive Cancer |
| primary_location.source.host_organization_lineage | https://openalex.org/P4324004213 |
| primary_location.source.host_organization_lineage_names | National Comprehensive Cancer |
| primary_location.license | |
| primary_location.pdf_url | https://jnccn.org/downloadpdf/journals/jnccn/21/7/article-p694.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of the National Comprehensive Cancer Network |
| primary_location.landing_page_url | https://doi.org/10.6004/jnccn.2023.0035 |
| publication_date | 2023-07-01 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W6633658626, https://openalex.org/W1965938576, https://openalex.org/W4281630496, https://openalex.org/W3206691421, https://openalex.org/W4360599532, https://openalex.org/W3003625721, https://openalex.org/W3095016275, https://openalex.org/W7075602604, https://openalex.org/W2996574710, https://openalex.org/W2938206352, https://openalex.org/W3021696184, https://openalex.org/W3049104202, https://openalex.org/W7019438879, https://openalex.org/W3010944770, https://openalex.org/W3024247862, https://openalex.org/W7075699191, https://openalex.org/W2113222623, https://openalex.org/W2062138514, https://openalex.org/W2783112448, https://openalex.org/W2785610956, https://openalex.org/W4309412600, https://openalex.org/W3193026281, https://openalex.org/W4286294450, https://openalex.org/W7056551832, https://openalex.org/W7075283865, https://openalex.org/W7024798881, https://openalex.org/W2589049990, https://openalex.org/W2033161279, https://openalex.org/W2809889937, https://openalex.org/W3082935137, https://openalex.org/W4290860519, https://openalex.org/W2053954823, https://openalex.org/W3160870976, https://openalex.org/W3026641008, https://openalex.org/W4295882695 |
| referenced_works_count | 35 |
| abstract_inverted_index.2 | 11 |
| abstract_inverted_index.In | 0 |
| abstract_inverted_index.an | 54 |
| abstract_inverted_index.as | 65, 67, 95, 97 |
| abstract_inverted_index.at | 51 |
| abstract_inverted_index.of | 35, 48, 83, 104 |
| abstract_inverted_index.on | 53, 72, 81, 102 |
| abstract_inverted_index.to | 57, 68, 87 |
| abstract_inverted_index.The | 20, 45 |
| abstract_inverted_index.and | 16, 32, 42, 62, 74 |
| abstract_inverted_index.for | 5, 23, 29, 91 |
| abstract_inverted_index.new | 70 |
| abstract_inverted_index.the | 2, 30, 84, 88, 98 |
| abstract_inverted_index.NCCN | 3, 21, 89 |
| abstract_inverted_index.care | 34 |
| abstract_inverted_index.data | 71 |
| abstract_inverted_index.from | 60 |
| abstract_inverted_index.into | 10 |
| abstract_inverted_index.some | 82 |
| abstract_inverted_index.well | 66, 96 |
| abstract_inverted_index.were | 8 |
| abstract_inverted_index.with | 37 |
| abstract_inverted_index.2023, | 1 |
| abstract_inverted_index.These | 77 |
| abstract_inverted_index.Tract | 18, 25, 93 |
| abstract_inverted_index.basis | 56 |
| abstract_inverted_index.focus | 80 |
| abstract_inverted_index.least | 52 |
| abstract_inverted_index.meets | 50 |
| abstract_inverted_index.newly | 99 |
| abstract_inverted_index.panel | 47 |
| abstract_inverted_index.annual | 55 |
| abstract_inverted_index.recent | 85 |
| abstract_inverted_index.review | 58 |
| abstract_inverted_index.Biliary | 17, 24, 92 |
| abstract_inverted_index.Cancers | 7, 26, 94 |
| abstract_inverted_index.cancer, | 39 |
| abstract_inverted_index.current | 73 |
| abstract_inverted_index.divided | 9 |
| abstract_inverted_index.experts | 49 |
| abstract_inverted_index.provide | 27 |
| abstract_inverted_index.section | 101 |
| abstract_inverted_index.updates | 86 |
| abstract_inverted_index.Cancers. | 19 |
| abstract_inverted_index.Insights | 79 |
| abstract_inverted_index.emerging | 75 |
| abstract_inverted_index.entities | 64 |
| abstract_inverted_index.evaluate | 69 |
| abstract_inverted_index.external | 63 |
| abstract_inverted_index.internal | 61 |
| abstract_inverted_index.patients | 36 |
| abstract_inverted_index.requests | 59 |
| abstract_inverted_index.separate | 12 |
| abstract_inverted_index.testing. | 106 |
| abstract_inverted_index.Carcinoma | 15 |
| abstract_inverted_index.molecular | 105 |
| abstract_inverted_index.published | 100 |
| abstract_inverted_index.Guidelines | 4, 22, 78, 90 |
| abstract_inverted_index.evaluation | 31 |
| abstract_inverted_index.principles | 103 |
| abstract_inverted_index.therapies. | 76 |
| abstract_inverted_index.gallbladder | 38 |
| abstract_inverted_index.guidelines: | 13 |
| abstract_inverted_index.extrahepatic | 43 |
| abstract_inverted_index.intrahepatic | 40 |
| abstract_inverted_index.Hepatobiliary | 6 |
| abstract_inverted_index.comprehensive | 33 |
| abstract_inverted_index.Hepatocellular | 14 |
| abstract_inverted_index.recommendations | 28 |
| abstract_inverted_index.multidisciplinary | 46 |
| abstract_inverted_index.cholangiocarcinoma, | 41 |
| abstract_inverted_index.cholangiocarcinoma. | 44 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 98 |
| countries_distinct_count | 9 |
| institutions_distinct_count | 41 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6499999761581421 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.99958688 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |